The untold story - Cancer Council NSW - Cancer Prevention ... · Cancer Council NSW connects people and organisations to the cancer cause. Together we can build insights into the

Theuntoldstory

2011

Research Activity Report

Message from the CEO. . . . . . . . . . . . . . . . . . . . . . . . . . . 2

Ten years of cancer research . . . . . . . . . . . . . . . . . . . . . . 4

Cancer Council NSW: a snapshot . . . . . . . . . . . . . . . . . . 6

Battling cancer of the brain . . . . . . . . . . . . . . . . . . . . . . . 8

Separating sport and sponsorship . . . . . . . . . . . . . . . . . 10

Hunting for viral links with oesophageal cancer . . . . . . 12

Learning more about Barrett’s oesophagus. . . . . . . . . . 14

Getting the word out about liver cancer. . . . . . . . . . . . . 16

Gaining new insights from colorectal cancer data . . . . 18

Patterns of pancreatic cancer care . . . . . . . . . . . . . . . . 19

Uncovering the progression of pancreatic cancer . . . . 20

Clearing the way for insights . . . . . . . . . . . . . . . . . . . . . 22

Finding out more about the unknown . . . . . . . . . . . . . . 24

Appendices

Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Grants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Publications, presentations and posters . . . . . . . . . . . . 32

Board and committees. . . . . . . . . . . . . . . . . . . . . . . . . . 40

Table of contents

Mission To defeat cancer through engaging the community

Cancer Council NSW connects people and organisations to the cancer cause. Together we can build insights into the significance of cancer in our lives and contribute our talents towards the vision of cancer defeated. We work across all cancers.

The impact from our work together will be visible in changing:

The lives of cancer patients and carers

Scientific knowledge

Community understanding and behaviour

Society, policy and practice to advance cancer control.

Increasingly, people will work in organisations and live in families and social settings which advance the control of cancer and where resources (people, ideas, services and funds) are developed globally and locally to meet the challenges of cancer.

Our Vision Cancer defeated

Our vision will be realised when lives are not cut short nor the quality of life diminished by cancer.

ToToToToToTTo dddddefefefefee eaeaeaeaeaae t t tt cacacaacancncncnccererere ttthrhrhhrh ouououo ghghghhhhhh eeeeeengngngnggggagagagaaaggininninnng g g gggththththht e e eeee cococococommmmmmmmmmmmununuunnnititityyyyy

CaCaCaCaCCaC ncncncnccerererre CCCCCouououuo ncncncnncillilli NNNNNNSWSWSWSW ccccconononnoo nenennen ctctctts s s pepepeeopopopoo leleleel aaaaandndndn ooooooorgrgrgganananaaaa isisisatatatatattioiooooiii nsnsnnn totototoo tttthehehhee cccanananannnceceeceer rr cacacacausususu e.e.e.e. TTTTTTogogogoogeteteetheheheer r r weweweeweewewe cccccananana bbbbuiuiuiildldldddddd iiinsnsnsnsnsnn igigiggggghththth sss innintototoooo tttthehehehe sisisiss gngngnnnnifiifiififificacacaccccc ncncnce e e ofoffoffo cccanannncecececec r r inininnnnnn oooururur llivivvveseses aaandndndn ccconononntrtrribibibbbbutuutu e e e ououour r rr tatataleleeentntntts s stotototottowawaawaww rdrdrdrdrdr s s ss thththeee vivivv sissisis ononon ooff f cacaacacancncncerererrr dddefefefeee eaeaeaeaaeeaatetetet d.dd. WWWWWWeeee wowwooorkrkrkrk aaacrcrrososososs s salalalallll cacacacaac ncncncnccererere s.s.s

ThThThThThTT e e eeee imimimimpapapap ctctcttt ffffrororoom mm ououour r rr rr wowoworkrkrkrrkr ttttogogoggoo eteetheheherr r wwiww llllll bbbbe ee e vivivvv sisis blblbbb e e e ininnn cccchahahhhangnggngngininnng:gg:g:

ThThThhe e e lililllilll vevevevvevvvessss ofofofofooooo ccccccananaannncececeeeer r r papapapappap tititt enenentststss aaaandndnd cccarararra erereree ss

ScScSccieieientntnn ifiifificc c knknnnnknowowowwleleedgdgdggggeeeee

CoCoCooCommmmmmmmmmmunununu ititty y y unununndededeeersrsrstatataandndndnn ininnnngggggg anananna ddd bebebebbbb hahahavivviouououurrrrr

SoSoSooSocicicicc etetety,y,y, pppppppppolollolooooo iciccciccy y y anananannanaannnnd d d prprpp acacacctititicecece ttto o o adadadaaa vavancncnce e eee cacacaancncncererer ccccononnononnnnntrtrtrt ololol.

InInInIncrcrcrcc eaeaeaeasisiss ngngngnnnnglylylyy,,, pepepepppp opopopleleeee wwwiliilll wowowoorkrkrk iin n n ororororo gagagganininin sasaaasaaaatititionononns s s anannanaa d d d lililiveveevvvvvevv iinnnnnfafaffamimimimilililililill eesesese aaaaaaaaandndddddd ssssococcoccco iaiaalll seseettttttinningsgsgsggs wwwhihihhichchchhhh aaadvdvdvanananncececec tttheheheh ccconononontrtrrrololol oooof f cacacaancncncnccncereree ananannnd d ddd whwwhwhwhhwww erererere e e rereresososoourururu cececeec s s ssss (p(p(p(pppeoeoeoeeeooeeeee plplpple,e,e iidedededdddd asasaassssss,,, seseservrvrvrvrvvvicicicceseses aaaaandndndnddddnd fffununununuuuu dsdsds) ) ) arararaaa e ee eedededededed vevevevevevevelolollooopepeppeed d dd d glglg obobobalalala lylylyyy aaaandndnddd lllocococcccccalalllalalala lylyly ttto o oooo memeemeetetetttte ttttheheheee ccchahahhhahaalllllllenenengegegeges s sss ss ofofof cccccananaancecec r.r.rr

CaCaCaCaCaaCCaaancnccncncn erererereerrrerrrr dddddefefefeffffeaeaeaeaeaaateteteteeet dddddddd

OuOuOuOOOOOuOOur r r rrr vivivivviv sisisisionononoon wwwwwwililillll bebebebee rrrreaeaeaeee lilillliseseseses ddd whwhwhwhhw enenenen llivivivvi esesessss aaaaarererere nnototot cccccututuuuutut ssshohohohoortrtrttt nonononnonoonor r r thththththhe e eee ququququuualaalaalititttty y yyy ofofofo lllllififififi e e ee dididdimimimimininnishshsshededededede bbby y y cacacaacaaaaaaaaancncnccnccererere ..

Cancer Council NSW Research Activity Report 2011 1

Our vision

Cancer defeated

Our vision will be realised when lives are not cut short nor the quality of life diminished by cancer.

Our mission

To defeat cancer through engaging the community

Cancer Council NSW connects people and organisations to the cancer cause. Together we can build insights into the significance of cancer in our lives and contribute our talents towards the vision of cancer defeated. We work across all cancers.

The impact from our work together will be visible in changing:

The lives of cancer patients and carers

Scientific knowledge

Community understanding and behaviour

Society, policy and practice to advance cancer control.

Increasingly, people will work in organisations, families and social settings which advance the control of cancer and where resources (people, ideas, services and funds) are developed globally and locally to meet the challenges of cancer.

“We are continuing to work hard to ensure our research activities are closely connected to the community and the needs of cancer patients and caregivers.”

“Weconto to ouactarecontheanof patcar

Dr Andrew Penman AMChief Executive Officer

2

Message from the CEO

As the largest non-government funder of cancer research in NSW, Cancer Council NSW is able to drive remarkable discoveries. We invested $16 million into research in 2011, bringing our research investment over the past 10 years to a total in excess of $100 million.

To fund this research, we rely on the generosity of our supporters – and we make sure that the largest segment of every donor dollar is committed to research activities.

Our strategy focuses on funding world-class, groundbreaking research that covers all aspects of cancer – particularly high-mortality and high-impact cancers, many of which are traditionally underfunded. This strategy is designed to ensure no cancer is ignored.

We value independence, forward thinking, courage and collaboration in our researchers both internal and external to Cancer Council. This approach has been rewarded this year with a number of significant breakthroughs. For example, Associate Professor Diona Damian’s research into skin cancer uncovered the potential role of vitamin B3 in preventing skin cancer by helping with DNA repair. This will add another tool to prevent this common cancer in Australians.

Another major success was achieved by our internal Cancer Council NSW researchers, who showed that Australia’s Pap smear screening frequency recommendations could safely be changed from two to three years. As a consequence of this work, the prevention of cervical cancer may become a lesser burden for millions of women.

Turning research into action

While research into cancer is vital, we also need to translate it into action. Cancer Council NSW is committed to using our resources and the results of our funded research activities to initiate changes in cancer policies and practices.

Our research into how children are influenced by sport sponsorship from companies marketing unhealthy food and drink products is being used to boost calls for changes in government policy. Similarly, the findings of our collaborative research into the needs of brain and pancreatic cancer patients, their carers and their families

are being used as the foundation for the creation of support packages and informational DVDs about these cancers.

We have driven new, practical and innovative research into cancers that would otherwise not receive the resources they need (including pancreatic, bowel, liver, brain and oesophageal cancers) through a series of strategic research partnerships across Australia. For example, although brain cancer is the most common cause of cancer death in people below the age of 39, research into this type of cancer attracted only 2.2% of all cancer research funding in NSW in 2004–06. To change this, Cancer Council NSW funded over $4.8 million worth of grants in brain cancer research during 2011 alone, and more than $9 million over the last five years.

Looking to the future

The rapidly changing world of cancer research means that our strategy must look ahead and anticipate new discoveries.

To ensure we support the development of future research breakthroughs, we have made a significant investment in genotype-guided cancer therapy, which we see as having enormous potential for creating new genetic approaches to treating – and potentially preventing – cancer.

Other areas which will bring significant benefits in the future are the potential development of our cancer biobank and our large population studies. Both the Cancer Lifestyle and Evaluation of Risk (CLEAR) Study, conducted by our internal Cancer Research Division, and the 45 and Up Study, conducted in collaboration with the Sax Institute, are likely to deliver invaluable insights into the background lifestyle and genetic factors influencing cancer risk.

Every day, 100 people will be diagnosed with cancer. At Cancer Council NSW, we are committed to funding research to make a difference in the fight against all cancers. Thanks to you, we can continue to do so.

Dr Andrew Penman AM Chief Executive Officer

Message from the CEOIn 2011, Cancer Council NSW has again been leading research into major and emerging types of cancer. Our commitment to research stretches across many areas and is dedicated to making a significant contribution to understanding the causes, prevention, treatment and cure of cancer.

This Research Activity Report presents just a small snapshot of the exciting work that is being undertaken by groups of dedicated and talented researchers. Their work builds our knowledge about cancer and its causes, and establishes the best ways to translate these findings into actions that will help the lives of people as they face the cancer journey.


Although cancer remains a major scourge in the community, much has been achieved in the past 10 years when it comes to unlocking its secrets and improving the lives of those affected by it.

Statistics show that unmistakable progress has been made in the fight against cancer. While the number of people diagnosed with cancer has crept up over the past 10 years, the number of people dying from cancer has fallen by 13%. Survival rates for almost every cancer have improved, with the 5-year survival rate for stomach cancer increasing by over 30% since the early 1990s. These improvements would not have been accomplished without the breakthroughs made by cancer researchers.

Our achievements

Over the past 10 years, the research undertaken and funded by Cancer Council NSW has been an important element in achieving improved survival rates. The research teams we have funded have made significant and exciting breakthroughs. Through their dedication and hard work, they have unlocked the secrets of cancer cell immortality, reduced the death rate from leukaemia, and developed a new drug that is now saving the lives of women with ovarian cancer.

Our researchers were the first to quantify the significant differences in cancer mortality – particularly from breast cancer – between Aboriginal and non-Aboriginal Australians.

Another significant achievement of our funded research in the past 10 years has been the discovery of two new possible cancer treatments targeting the power supply of cancer cells. This work may be able to help with brain and pancreatic cancers, which are currently incurable.

We continue to participate in the largest study of healthy ageing in the Southern Hemisphere, with Cancer Council NSW playing a vital role in the 45 and Up Study. Data from this study will potentially be used to create one of the world’s largest biobanks.

Research into practice

Ensuring research findings are translated into practical actions is an essential part of our work. We are dedicated to funding research that can change real-world outcomes, and to supporting its findings as they are incorporated into clinical and policy practice.

We have funded a number of clinical trials, evaluations of chemotherapy techniques, and other practical research that has improved the diagnosis and treatment of cancer. Our Strategic Research Partnership (STREP) grants are founded on the concept of translational research – research designed to strengthen real-world applications.

A major success has been the work of our mathematical modelling team, who documented the impact of human papillomavirus (HPV) vaccination on future cervical cancer incidence. This research has influenced vaccination and cervical screening policies in Australia, New Zealand, China and the United Kingdom.

We have been active in lobbying for changes in tobacco legislation. Based on the results of research into the effects of passive smoking, bans have been implemented on displaying tobacco products in retail outlets, smoking in cars with children, and smoking in playgrounds, hotels and clubs.

Each of these research-based activities marks a significant achievement and another success in the continuing fight against cancer.

Investment in research over five years ($ million)

Ten years of cancer researchCancer Council NSW has been at the forefront of cancer research for a decade, with remarkable results.

$16,053,000

$14,282,000

$14,379,000

$12,921,000

$10,712,000$0

$5

$10

$15

$20

20082007 2009 2010 2011

4

Ten years of cancer research

Who we areWe are an independent and forward-thinking community of people, where ideas and charity come together to make a difference in the fight against all cancers.

What we doBy funding and undertaking world-leading research into prevention strategies and new treatments, as well as providing advocacy and support to those affected by cancer, we are working towards realising the vision of a society where lives are not cut short – nor the quality of lives diminished – by cancer.

Our researchBy investing in the most promising research, adopting up-to-date technologies, rapidly responding to breakthroughs, swiftly dispelling myths, and conducting population-based forecasting to meet future needs in prevention, services, screening and vaccinations, Cancer Council NSW continues to make a real difference in the fight against cancer.


Investment in strategic priorities Cancer Council NSW has a research strategy that supports cancers of poor prognosis and those where the level of funding does not reflect the burden of disease. Our research portfolio demonstrates our commitment to providing mechanisms for discovery in these cancers.

20082007 2009 2010 2011

Types of research funded in 2011 Cancer research by governments, charities and foundations in Australia was found to be heavily skewed towards the basic science end of the spectrum in a 2003–05 report, with most research into fundamentals (44%), followed by treatment (20%). Cancer Council NSW, by contrast, has consistently funded more practical and translational research as shown on the graph (left).

Investment in cancers compared to their incidence and mortality

% of 2007–2011 research expenditure

Standardised incidence, Australia 2008

Standardised mortality, Australia 2008

Cancer Council NSW has the flexibility to actively respond to new opportunities and needs in research. We monitor trends in cancer incidence and research funding, and engage with consumers, practitioners, researchers and policymakers to provide timely and appropriate support for research. 0

10

20

30

40

50

60

70

80

90

100

Cancer Council NSW: a snapshot

Causes – 10.1%

Detection – 15.7%

Prevention – 6.7%

Treatment – 30.3%

Survivorship – 5.6% Fundamental – 22.5%

Model systems – 9.0%

Pancreatic

Liver

Oesophageal

Colorectal

Brain

Incidence/mortality per 100,000 peoplePercentage of research expenditure

$1,500,500

$500,000

$0

12%

10%

8%

6%

4%

2%

0%

Non-H

odgk

in’s l

ymph

oma

Melano

maLu

ngLiv

er

Leuk

aemia

Colorec

tal

Breast

Brain

Oesop

hage

al

Ovary

Pancre

as

Prostat

e

$1,000,000

$2,000,000

$2,500,000

$3,500,000

$3,000,000

6

Cancer Council NSW: a snapshot

Our research capabilities and reach are also enriched by our international network, with hundreds of collaborations with academics, organisations, networks and communities. Our national and international collaborations enable us to extend our capabilities and accelerate breakthroughs in ways to prevent, diagnose, treat and manage cancer.

Our global collaboration and reach

0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

Testi

cular

Endoc

rine

Bone a

nd co

nnec

tive t

issue

Non-H

odgk

in’s l

ymph

ona

Head

and

neck

Myelom

a

Skin (n

on-m

elano

ma)

Haemato

logica

lLu

ng

Oesop

hage

al

Ovaria

nLiv

er

Melano

ma

Prosta

te

Colorec

talBrai

n

Breast

Leuk

aemia

Pancre

atic

0

10

20

30

40

50

60

70

2008 2009 2010 2011

Europe – 22

Australia – 122 Asia/South Pacific – 24

US/Canada – 17

Africa – 20

7 Cancer Council NSW Research Activity Report 2011

Our internal research group, the Cancer Epidemiology Research Unit (CERU), is one of the largest public health cancer research operations in Australia, with 40 scientific staff – plus students and volunteers – working with more than 150 collaborators.

Publications/presentations Location of collaborators

Publications

Presentations

Research by cancer type over five years (2007–2011)

We aim to drive research in all cancers for all people. Our grants cover both researcher-initiated projects, which are not traditionally priority driven, and Strategic Research Partnership (STREP) grants, which are focused on our priority areas in cancer. This allows us to cover a broad range of cancers, while still investing in priority cancers.

% of investment

CERU publications and collaborations

“The beginning months are the easy part – it’s the long term. It just shatters your life.”

Justin was diagnosed with brain cancer in July last year. After he went to hospital, the surgeon, Dr Jonathon Parkinson, originally booked him in for a surgery in four days time. But after watching Justin for a few minutes, he changed his mind: “I’m taking him now, we’re going to operate tomorrow. He can’t wait”.

After the surgery, Justin couldn’t write, read, talk or walk. But thanks to an incredibly supportive medical team and his friends, he’s just got his driver’s licence again and is about to start what will hopefully be his last round of chemotherapy. His advice to anyone else in the same situation? “Just keep fighting, and stay positive.”

Justin and Wendy Survivor and carer

benthsy palonst sr lif

diagnoseAfter he weon Parkinsgery in fouustin for aI’m takingmorrow. H

urgery, Jusut thanks tam and hience againlly be his to anyonefighting, a

d Wendy nd carer

“The moneasythe It juyour

Justin waslast year. ADr Jonathoin for a surgwatching Jhis mind: “Ioperate tom

After the suor walk. Bumedical teadriver’s licewill hopefuHis advice“Just keep

Justin andSurvivor a

8

Battling cancer of the brain

Battling cancer of the brainProject: Dynamin inhibitors as new anti-cancer drugs for brain cancer

Brain cancer is extremely difficult to treat, with no significant improvement in survival rates in more than two decades. A new drug treatment, which works by interfering with cancer cell division, has reduced mouse brain tumours by more than 80%, with limited apparent side effects. Researchers hope this new drug will perform better than existing chemotherapy drugs and have fewer adverse effects.

Brain cancer is the leading cause of cancer death in people below the age of 39, and it accounts for more than 30% of cancer deaths in children under the age of 10.

The most common, lethal and difficult-to-treat type of brain tumour is glioblastoma. A key characteristic of this deadly cancer is its rapid growth, as the cancer cells divide and spread faster than normal cells. This rapid growth is what many cancer drugs aim to target and is the reason many patients treated for cancer lose their hair (as hair follicles are some of the fastest-growing cells in the body).

With no significant improvement in survival rates for patients with this type of brain cancer in almost two decades, researchers at the Children’s Medical Research Institute have been working on an enzyme (dynamin) that cells use to help them divide and grow.

Although there are three types of this enzyme, the research group is concentrating on ways of inhibiting dynamin-2. This could possibly prevent cancer cells from multiplying, as researchers have shown that dynamin-2 inhibitors not only stop the cancer from dividing, but also actually cause cell death if the cells try to divide.

These dynamin-2 inhibitors are predicted to not affect normal cells that are not dividing, and may be more effective and have fewer side effects than existing chemotherapeutic drugs.

What we achieved this year

In 2010, researchers identified a drug that successfully reduced tumour size in a mouse model of brain cancer. This year, they have attempted to understand exactly why it worked. Exhaustive analysis found that the drug stimulated cell death in cells that contain low amounts of a protein that prevents cell death, which led to suggestions that the drug might work better when used in combination with other chemotherapy drugs to increase its effectiveness and improve patient outcomes. Encouraging studies conducted on mice have also suggested that the drug has limited side effects.

During 2011, the researchers developed several second-generation compounds based on the original drug. These compounds were found to be equally effective at blocking dynamin-2 function in cells, but have enhanced cell-killing properties and are predicted to have improved drug characteristics (including the ability to enter the brain) compared to current brain cancer treatments.

Future activities

Future research will aim to confirm that dynamin inhibitors are suited to being used as drugs for brain cancer treatment, as they are better able to kill cancer cells and have few side effects.

It is expected these dynamin inhibitors will be tested in clinical trials and used in human cancer treatment. Cancer Council NSW is continuing to support this exciting research, and awarded the research team another grant in 2011.

What impact will it have?Current chemotherapy drugs to treat glioblastoma (a type of brain cancer) do not actually increase long-term survival rates, so new targets and strategies are required to treat this devastating cancer. This research project may lead to the development of novel small-molecule dynamin inhibitors that have the potential to be used alone, or in combination with conventional chemotherapy, for the treatment of glioblastoma.

Over the long term, this project may lead to the identification of a dynamin-inhibitor compound that can be pursued for testing in clinical trials for the treatment of glioblastoma.

Lead researcher: Dr Megan Chircop, Biomedical Researcher, Children’s Medical Research Institute, Westmead.


Separating sport and sponsorshipProject: Food and drink company sponsorship of children: publicity or philanthropy?

Being overweight or obese increases the risk of developing bowel, pancreatic, endometrium, kidney, breast and oesophageal cancers. Cancer Council NSW aims to prevent obesity through multiple approaches, including providing education on healthy food choices and improving access to healthy food. However, the promotion of unhealthy foods undermines efforts to improve nutrition. Cancer Council NSW is investigating the extent of unhealthy food sponsorship in children’s sport, one of the ways that this type of food is promoted to children. The research also assesses the influence this sponsorship has on children’s food choices, and considers alternatives.

With a quarter of Australian children currently overweight or obese, it is important to help parents in their quest to raise healthy children and to lift awareness of the links between cancer and obesity. This is particularly important because the eating habits children develop while young stay with them for life.

Although there are numerous causes of childhood obesity, exposure to high levels of unhealthy food marketing is one factor affecting the food and drinks children favour, pester their parents to buy, and consume.

Extensive research indicates that, in general, children are exposed to high levels of food marketing, most of which is for unhealthy food and drinks containing large amounts of fat, sugar and/or salt. This occurs through television advertisements during children’s programs; on-pack promotions for competitions and giveaways; billboards; advertisements in children’s magazines; and online and interactive games on food manufacturers’ websites.

Increasingly, sport sponsorship is being used for promotion of food and drink products aimed at children, either through financial or in-kind assistance. Although such sponsorship may be an important funding source for sport, this type of branding and promotional activity by the manufacturers of unhealthy food and drinks can undermine the health-promoting goals of sport.

Corporate sponsorship is designed to help build a connection between the sponsoring company’s products and the sporting event, which encourages children’s positive feelings and attitudes towards sport to be transferred to the marketed products. This can then influence children’s product purchases.

Currently, Australia has no regulations limiting the marketing of unhealthy food and drink products through sports sponsorship. This is despite recommendations from the World Health Organisation for such marketing restrictions in settings where children gather, including sporting activities.

Studying sport sponsorship

To provide more information and clear data on this important issue, a three-year research project in conjunction with the Prevention Research Collaboration at the University of Sydney examined food and drink company sponsorship of children’s sport in NSW. An Australian Research Council (ARC) Linkage Grant funded this important work.

The study measured the extent of children’s exposure to food marketing in the sports most popular with children (see chart). It examined the views of parents and sporting club officials about the influence of unhealthy food company sponsorship on children, and investigated whether they would support alternative funding arrangements for sport. The research team also studied the impact of unhealthy food sponsorship on children’s food purchases and preferences.

This work represents the first international study to comprehensively investigate the extent of unhealthy food sponsorship in children’s sport and to assess the influence this type of sponsorship has on children’s food choices and purchases. In the future, the results could influence government policy.

10

Separating sport and sponsorship

What impact will it have?This is the first international study to comprehensively investigate the extent of unhealthy food sponsorship in children’s sport and to assess the influence of this type of sponsorship on children’s food choices and purchases. The project findings have provided much-needed, detailed evidence to support government intervention to reduce children’s exposure to food marketing through sporting clubs. Researchers expect the results of the project will drive major change in the sponsorship of children’s sports.

Lead researcher: Bridget Kelly, PhD candidate, Prevention Research Collaboration, University of Sydney

Co-researchers: Louise Baur, University of Sydney; Adrian Bauman, University of Sydney; Lesley King, University of Sydney; Kathy Chapman, Cancer Council NSW; and Ben Smith, Monash University

The responses gathered during the research project provided much-needed empirical evidence to support the notion of government intervention to reduce children’s exposure to food marketing through sporting clubs. The research team also explored a range of policy options to support the development of health-promoting sports clubs that could reduce children’s exposure to unhealthy food marketing.


During this project, the research team produced seven journal publications and one summary report related to food and drink company sponsorship of children’s sport and the promotion of health and nutrition through sport. Of these, four were published in 2011, the final year of the project.

In addition, telephone surveys were carried out with 825 parents in 2011, to investigate the relationship between unhealthy food, drink and alcohol sponsorship and both children’s and elite sport. Around one-quarter of parents reported at least ‘sometimes’ being pestered by their child to buy a food or drink product from a company that sponsored their favourite elite sports team or their own local club. More than half of parents (60%) were ‘very’ concerned about unhealthy food and drink companies sponsoring children’s sports clubs.

An online survey of 243 children was also conducted in 2011. Respondents were asked if they could recall sponsors of their favourite elite athlete, sports team or sporting event. Questions were then raised in regard to what they thought about these companies and if sponsorship affected the products they bought and ate. More than half of children thought elite sport sponsors

were either ‘very’ or ‘a little’ cool (59%), exciting (50%) and fun (51%). One-third of children reported that they ‘often’ or ‘sometimes’ bought or asked their parents to buy sponsors’ products.

In-depth interviews were conducted with 22 companies and other funding bodies in 2011, to determine the level of support for an alternative healthy sports club program based around the goal of reducing children’s exposure to unhealthy food sponsorship and to address other health-promoting behaviours. Such a program was found to have a high level of interest from corporate and philanthropic organisations and is currently being considered for further piloting.

Healthy vs. less healthy food and drink sponsorship of children’s sport

Mostly older

Mixed age

Mostly younger

By age of club members

0 20 40 60 80 100

less healthy

healthy

Proportion of sponsors (%)


“We wanted to find out whether certain strains of human papillomavirus (HPV) caused oesophageal cancer but soon realised that we needed around 5,000 specimens to prove our point. Our own small biobank had only 1,500 blood specimens, so we contacted our colleagues with biobanks across the world and managed to gather a total of 5,000 serum samples from Australia, South Africa, Iran, China, Western Europe and Brazil.

“All these studies added up to 55 years’ worth of data collection. By collaborating with these biobanks, we will be able to answer this question in three years. If we had started from scratch, it would have taken each of us 55 years to achieve the same aims.”

Associate Professor Freddy Sitas Director, Cancer Research Division, Cancer Council NSW

“Biobanks allow researchers to answer critical questions much easier, faster and cheaper than before.”

hree years. If we had startequq estion in thould have ttakakenen each of usscscraratctch,h, it woeve the same aaims.”years too aacchi

rofessor FrFreeddy SitasAssociate Prncer Resesearch DivisiDirector, Cannccilil NNSWCancer Cou

12

Hunting for viral links with oesophageal cancer

Hunting for viral links with oesophageal cancerProject: The InterSCOPE Study and oesophageal cancer

Oesophageal cancer is a rapidly fatal and neglected cancer in Australia, despite being the sixth most common cause of cancer deaths worldwide. Researchers know that lifestyle activities, including smoking cigarettes and drinking alcohol, are the main causes of this cancer. The InterSCOPE Study, a collaboration between investigators in nine countries, is investigating the possible links between the human papillomavirus (HPV) infection and oesophageal cancer.

The aim of the InterSCOPE Study is to identify whether certain strains of human papillomavirus (HPV) are likely to cause oesophageal cancer, particularly of the squamous cell type. HPV causes several squamous cell cancers, mainly of the cervix (hence the HPV vaccine, which prevents cervical cancer), but also in other genital sites and parts of the oral cavity.

Smoking and alcohol are the main causes ofthis cancer, but researchers have also discovered inconsistencies in different parts of the world. These inconsistencies have led to a number of past investigations into diet, mouldy maize and the role of HPV. The results, however, have been inconclusive.

Animal strains of HPV cause cancer of the oesophagus in cows and other animals, so if a relationship can be identified in humans, the impact of the HPV vaccine would be far more wide-ranging than originally thought. Preliminary evidence from this study suggests that HPV does not cause oesophageal cancer in the majority of cases, but there will not be a definitive answer until the research is complete.

To make a convincing statement about any causal relationship, researchers recognised that they needed first to combine data from a large number of studies. By pooling and comparing data from many different countries and searching for trends consistent across all locations, it would be possible to determine whether HPV could be increasing the risk of oesophageal cancer.

Over the past three years, the research team approached international researchers who have conducted studies on oesophageal cancer – from

Australia, China, South Africa, Brazil, Poland, Russia, Romania, the Czech Republic and Iran. Leading institutes such as the US National Cancer Institute, the World Health Organisation International Agency for Research on Cancer, the Queensland Institute for Medical Research, the German Cancer Research Centre and the South African National Health Laboratory Service have all collaborated to expand the size of the investigation, making it the largest of its kind in the world. About 4,000 people with and without oesophageal cancer were compared. This would have taken about 55 years if anyone were to start this study from scratch.

Extensive data from each research site were forwarded to Cancer Council NSW for analysis. Blood results were combined with the data and compared (after adjusting for important lifestyle factors such as smoking and alcohol consumption) to provide a more definitive answer about any relationship.


The results of the InterSCOPE Study were published in the prestigious Journal of the National Cancer Institute. The paper noted a possible (weak) association between HPV and oesophageal cancer, but only for certain forms of the HPV virus.

The researchers are now continuing work with their German colleagues in trying to detect the HPV virus in about 90 stored tumour biopsy samples. These were selected from people who had a blood profile suggesting a better chance of finding the presence of the virus and establishing a causal link.

What impact will it have?The study is designed to provide a clear picture of a link between HPV and oesophageal cancer, to inform future HPV vaccine programs. Research into the link between HPV and oesophageal cancer has been conducted since 1982, and until now, studies have been inconclusive. Thanks to the level of international collaboration, this is the most comprehensive study yet of the connection between these two conditions, and is in a position to finally deliver an authoritative answer.

Lead researcher: Associate Professor Freddy Sitas, Director, Cancer Research Division, Cancer Council NSW


Learning more about Barrett’s oesophagusProject: PROBE-NET – investigating the link between Barrett’s oesophagus and oesophageal cancer

Barrett’s oesophagus is a potential precursor for adenocarcinoma of the oesophagus (a type of oesophageal cancer), and is a condition caused by acid reflux from the gut. Given the increased risk of oesophageal cancer among patients with Barrett’s oesophagus, researchers are seeking a reliable method to identify which patients with this condition will develop oesophageal cancer, so that earlier – and more effective – treatment for this deadly disease can be offered.

Oesophageal cancer research has been poorly funded relative to its impact on the Australian community, with only 2.7% of cancer funding in 2004–06 dedicated to researching this fatal disease. As the number of people with adenocarcinomas of the oesophagus is rapidly increasing in Australia, Cancer Council NSW is providing additional funding for research into this cancer and has listed it as one of the organisation’s top five research priorities. Patients with this cancer type face a poor prognosis and invasive treatment, pointing to the significant need for new approaches and more detailed information.

A large volume of clinical research shows that before being diagnosed with oesophageal cancer, most patients suffer from Barrett’s oesophagus, a problem generally caused by acid reflux from the gut. Approximately 12% of Australians experience reflux symptoms at least once a week, and more than 10% of these patients have Barrett’s oesophagus. Another potent risk factor is obesity, with recent research suggesting that patients suffering both obesity and frequent acid reflux have markedly increased risks of developing both Barrett’s oesophagus and oesophageal cancer. There are long-term data to show that the number of patients being diagnosed with these conditions is increasing each year, almost certainly due to the rising prevalence of reflux and obesity in our community.

As there is currently no way of predicting which patients will progress from Barrett’s oesophagus to oesophageal cancer, except by invasive endoscopic biopsy, most patients have advanced tumours by the time they are diagnosed. This means that the treatment options are limited and mortality rates are extremely high, with median survival now less than one year after diagnosis.

Because the likelihood of developing new and more effective therapies appears remote, new ways to reduce the burden of this cancer are essential. The current methods for assessing the risk of oesophageal adenocarcinoma are time consuming, and require taking samples with an endoscope and then conducting laboratory analysis.

Finding genomic markers

Some of the most promising research in this area is being undertaken by Professor David Whiteman from the Queensland Institute of Medical Research and co-investigators from St Vincent’s Hospital (Sydney), Flinders University (Adelaide) and the Peter MacCallum Cancer Centre (Melbourne). They are currently investigating genes and markers which might predict oesophageal cancer.

These research groups form part of the PROBE-NET (Progression of Barrett’s Esophagus to Cancer Network) consortium, which was created in collaboration with Cancer Council NSW. This consortium is trying to find new ways to identify people at high risk of developing oesophageal cancer, and to formulate new testing methodologies and translate them into clinical practice.

The team is using a variety of research techniques – including epidemiology, cell biology and integrated genomic analysis – to distinguish between the cases of Barrett’s oesophagus which will become oesophageal cancer and those which will not.

Potentially, this research will provide an opportunity to improve clinicians’ ability to diagnose likely oesophageal cancer patients, which will allow them to institute earlier treatment programs and offer patients a better chance of survival.

14

Learning more about Barrett’s oesophagus

What impact will it have?Potentially, this research will provide an opportunity to improve clinicians’ ability to predict which patients are at highest risk of oesophageal cancer, allowing doctors to institute earlier treatment programs and offer patients a better chance of survival.

The research includes a number of exciting areas of investigation, including the genetic mutations associated with oesophageal cancer, testing of new methods of diagnosis using lymph nodes, and trials of new cancer treatments.

Lead researcher: Professor David Whiteman, Queensland Institute of Medical Research


Since being awarded a Cancer Council NSW Strategic Research Partnership (STREP) grant of $1.4 million in 2006, the researchers and clinicians involved in the PROBE-NET consortium have been working to combine the existing activities of the network’s independent research groups into a coordinated national program.

This year, the researchers have made substantial progress in advancing their multi-site research program. They have now recruited 689 patients and collected more than 4,424 tissue samples, which will form a major component of the project’s growing, clinically annotated tissue collection. This tissue collection will eventually be among the largest of its type in the world, creating an invaluable resource for cancer researchers.

Few groups worldwide have the samples, skills and facilities to find new tests for Barrett’s oesophagus, so by bringing together the four leading research groups in Australia in this area,

the project has a unique opportunity to advance knowledge and practice in oesophageal cancer.

During 2011, the PROBE-NET investigators and students have co-authored research articles and written further research papers on Barrett’s oesophagus–related topics. Several of these articles are now under review.

The research network into oesophageal cancer has also expanded, with new collaborators joining from Westmead Hospital, Greenslopes Hospital (Brisbane), Nepean Hospital and The Alfred Hospital (Melbourne).

Future activities

In the coming year, the PROBE-NET consortium will be continuing its research. The group anticipates that during the remaining two years of the STREP grant, another ten scientific papers will be published. Its researchers have created a list of key priorities and they will be seeking to access additional funding to enable the multi-site program to grow.

1983

1982

1984

1985

1986

1987

1988

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2

4

6

8

10

Mortality – males Mortality – females Incidence – males Incidence – females

Oesophageal cancer rates in Australia

Rate per 100,000 people


“They showed my case to a world-leading liver expert, and she said that she had never seen anything like it.”

“They showmy case toworld-leadliver expershe said thshe had neseen anythlike it.”

“In 2002, they discovered a malignant tumour in my liver. Thankfully, I had a brilliant surgeon and he was able to get it out – I didn’t require chemotherapy or radiation, which was amazing. But in 2010, my blood tests revealed that I was at risk of developing another malignant tumour. They sent me for a scan, and in the meantime, my tumour marker count was going up to 65, and then it was 90.

“I went to see an endocrinologist, who said that my vitamin D was dangerously low and made me take vitamin D tablets. When I had my next tumour marker test, they rang me at work, which they never ever did. And the secretary said, ‘June, we want you to know what your reading was’. I thought, ‘Oh no, it’s going to be 200 or something’, and I‘m hanging on to a table at work. And she said, ‘It’s four’.

“I had tears running down my face. I had myself dead, preparing for the funeral, and she said, ‘It’s four, we can’t believe it, and we wanted to ring you straight away’.”

June and Greg Survivor and carer

It s four, we can t believe it,riringng yyouo straight away’.”

June andnd GregSurvvivivor and carer

16

Getting the word out about liver cancer

Getting the word out about liver cancerProject: ‘B Positive’ Program – preventing liver cancer through optimising hepatitis B diagnosis and treatment

Liver cancer is relatively uncommon in Australia, but it is one of the top five cancers among Asian Australians. Cancer Council NSW has developed the ‘B Positive’ Program to identify and improve the management of patients with chronic hepatitis B – to help reduce the number that go on to develop liver cancer.

In NSW, residents born in Vietnam, Hong Kong, Macau, Korea, Indonesia and China are 6 to 12 times more likely to develop liver cancer than non-Indigenous Australian-born individuals. As up to 80% of liver cancer in some communities is caused by chronic hepatitis B (CHB) infection, a program that prevents the progression to liver cancer can have a very significant public health impact. Early CHB detection and regular follow-up can halve the number of liver cancer cases and related deaths in this group.

The ‘B Positive’ Program provides health information to affected communities to encourage screening, and supports local general practitioners to identify and manage their patients with CHB. The ‘B Positive’ Registry was established to provide population-level data on the clinical characteristics of patients with CHB infection.


Patient recruitment rates have trebled in 2011, and 10 more general practitioners have joined the program. The ‘B Positive’ Registry interim data analysis highlighted the multicultural face of CHB infection in south-west Sydney, with 44% of participants born in Vietnam, 20% in China, 21% in other Asian countries and 11% in the Pacific Islands. As diabetes, obesity and high cholesterol levels were recorded in 14–29% of registry participants, the program is working in collaboration with the Macarthur Division of

General Practice to integrate CHB management into general practitioners’ chronic disease–management plans for these patients.

Our new research in 2011 spanned a broad number of fields. The researchers studied the barriers to liver cancer prevention and control; compared the cost of treating liver cancer between countries; and highlighted the need for a continuing medical education program for general practitioners about hepatitis B diagnosis and management.

Community and professional development work

Through a University of Sydney grant, the researchers are developing a course teaching medical students about health disparities, using hepatitis B case studies. They are also delivering educational programs to general practitioners on hepatitis B diagnosis and management, in collaboration with the Australasian Society of HIV Medicine.

The ‘B Positive’ team has developed a multilingual hepatitis B ‘travelling library’ resource for community-based organisations and local libraries, to raise community awareness of hepatitis B and liver cancer; and has provided information sessions in collaboration with Fairfield City and the Cabramatta Library.

What impact will it have?It is estimated that 185,000 people are living with chronic hepatitis B in Australia, but approximately one-third of them remain undiagnosed. Late diagnosis is a major contributor to hepatitis B–related liver cancer. The ‘B Positive’ Program is based on economic modelling suggesting that guideline-based management of chronic hepatitis B is more cost-effective than liver cancer screening, and can halve the number of deaths from liver failure and liver cancer.

Lead researcher: Dr Monica Robotin, Medical Director, Cancer Council NSW, and Senior Lecturer in Public Health, University of Sydney

Research team: Mamta Porwal, Debbie Nguyen, Yumi Patton – Cancer Council NSW; Melanie Kansil, Cathedral St Partners; Dr Khoo Chee, Macarthur Division of General Practice; Dr Miriam Levy, Liverpool Hospital; and Professor Jacob George, Storr Liver Unit and University of Sydney


Gaining new insights from colorectal cancer data Project: Cancer Epidemiology Research Unit colorectal cancer initiatives

Colorectal cancer, the second most common cancer in NSW, accounted for 13% of all new cancers and cancer deaths in the state in 2008. Obesity, a sedentary lifestyle and poor diet all place people at greater risk of developing colorectal cancer. Cancer Council NSW is working on several projects aimed at better understanding key aspects of this significant cancer.

One in 10 men and one in 15 women will develop colorectal cancer by the age of 85. In light of the high number of people that develop this cancer, Cancer Council NSW’s Cancer Epidemiology Research Unit worked on a number of epidemiological research projects related to colorectal cancer during 2011.

The first of these described general practitioner involvement in the referral process for this disease. Professor Dianne O’Connell and David Goldsbury, in collaboration with researchers from the University of New South Wales and the University of Sydney led by Professor Mark Harris, analysed in detail the referral pathways for NSW residents diagnosed with colorectal cancer. The research team also linked the treatment data collected in the population-based NSW Colorectal Cancer Care Survey with death records to provide data on longer-term survival outcomes for people diagnosed with colorectal cancer.

Two papers were written describing the results of this study and these are currently undergoing peer review. The first describes the impact on patient survival of receiving treatment according to recommendations in the National Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer. The second analysis describes the association between surgeon specialisation and outcomes (including disease recurrence and survival) for people diagnosed with rectal cancer in NSW.

The internationally recognised expertise of Cancer Council NSW’s modelling team (led by Associate Professor Karen Canfell) in relation to cervical cancer is now being used to evaluate various options for colorectal cancer prevention. Using a simulation modelling approach, the research team is assessing short- and long-term outcomes, and reviewing the cost-effectiveness of various scenarios of colorectal cancer screening.

Large-scale population studies

Another project in this area is using colorectal cancer data from the 45 and Up Study. This is the largest study on ageing in the Southern Hemisphere (with over 267,000 participants aged 45 and over) and is partially funded by Cancer Council NSW. Colorectal cancer data from the study are being used by a research team from Charles Sturt University, led by Dr Marianne Weber from Cancer Council NSW, to investigate the use of screening services in regional and rural NSW. This work aims to ascertain the educational programs required to encourage better use of the available screening services.

Cancer Council NSW’s ongoing Cancer Lifestyle and Evaluation of Risk (CLEAR) Study (see page 22), now has 741 participants with colorectal cancer. This participant group is now large enough to begin epidemiological analysis on genetic, lifestyle and environmental risk factors related to colorectal cancer, and this work will begin later in the year.

What impact will it have?Colorectal cancer is one of the key cancers affecting the NSW population, and the research projects being undertaken by Cancer Council NSW and our collaborators will provide valuable insights into a variety of areas. These include better understanding of referral pathways, the impact of different clinical management approaches, and the cost-effectiveness of various screening scenarios.

In addition, the investigation into the use of colorectal screening services in regional and rural NSW is likely to have a significant impact. If the study shows there is a lower uptake of colorectal screening in non-urban areas, work will be undertaken to improve educational programs about screening in these localities.

18

Colorectal and pancreatic cancer

Patterns of pancreatic cancer careProject: Pancreatic Patterns of Care Study

With no effective treatment for pancreatic cancer, patient care is an important component of this cancer’s profile. The Pancreatic Patterns of Care Study is examining the care of NSW and Queensland pancreatic cancer patients. It explores their supportive care needs and the impact this devastating disease has on the quality of life for patients.

Little is known about the patterns of care used by clinicians with patients suffering from pancreatic cancer. The Pancreatic Patterns of Care Study, funded by the National Health and Medical Research Council, is the most comprehensive Australian research to investigate the variations in the patterns of care and the survivorship experiences of patients with pancreatic cancer.

It is only by identifying current practice patterns and the unmet needs of patients with pancreatic cancer that there will be any improvement in the delivery of ‘best practice’ care for all pancreatic cancer patients.

Pancreatic cancer patients have the worst survival rate for cancer patients in Australia. This is caused by a number of factors, and has created a unique situation in terms of available treatments, patterns of care, supportive care needs and quality of life.

Currently, there is only scant information available on this area, so findings from the study will help with the development of clinical management guidelines for Australian pancreatic cancer patients. The results will also enable researchers to develop programs designed to target modifiable factors and specific clinical issues.

It is hoped that additional financial support will become available, so that this valuable information resource can be used to address a variety of other significant questions about pancreatic cancer, such as an assessment of the costs and benefits of the different management practices used with pancreatic cancer patients.


The identification of pancreatic cancer cases at the NSW Central Cancer Registry has progressed, with more than 860 patients identified for the study so far. Approval to extract treatment data from patients’ medical records has been obtained from 50 hospitals and cancer centres, with 600 patient charts reviewed to date.

In addition, Cancer Council NSW is providing $2.5 million over 5 years to the International Cancer Genome Consortium Project, which is studying the genetic changes associated with 50 types of cancer. Australia is part of the consortium mapping the pancreatic cancer genome.

What impact will it have?The data collected during this project will contribute to the development of a world-class information resource on pancreatic cancer patient care. Information gathered during the study will assist with the development of detailed disease-management guidelines for clinicians. These guidelines should help to improve the care of pancreatic cancer patients around Australia.

Lead researchers: Associate Professor Rachel Neale, Senior Research Fellow, Queensland Institute of Medical Research, University of Queensland; and Professor Dianne O’Connell, Senior Epidemiologist, Cancer Epidemiology Research Unit, Cancer Council NSW


“I’m a specialist pancreatic surgeon at Bankstown Hospital, and I also research pancreatic cancer at the Garvan Institute of Medical Research. Pancreatic cancer is a devastating illness. Most of the symptoms are very vague, like a constant feeling of having an upset stomach, and it’s very difficult to diagnose early.

“The only chance of a cure is surgery that only a fifth of patients are suitable for. However, we are making progress – some pancreatic cancer surgeries used to have a mortality rate of 20–25%, and it’s now down to around 3–4%. Australia is at the forefront of pancreatic cancer research, and I’m proud to be part of the team sequencing pancreatic cancer as Australia’s contribution to the International Cancer Genome Consortium.”

Professor Andrew Biankin Head, Pancreatic Cancer Research, Garvan Institute of Medical Research

“The main risk for pancreatic cancer is just bad luck. Most of them develop for reasons we don’t understand yet.”

“

us a a s a e o e o o parereseseararchc ,, and I’m proud to be psequencing ppancreatic cancercontributionon to the InternationGenoomeme Consortium.”

Professor Andrew BiankHead, Pancreatic CanInstitute of Medica

20

Uncovering the progression of pancreatic cancer

Uncovering the progression of pancreatic cancer Project: Desmoplasia in pancreatic cancer: role of pancreatic stellate cells in cancer progression

Pancreatic cancer is a leading cause of death in Australia, with most patients dying within a few months of diagnosis. Surgery, chemotherapy and radiation have only limited benefit. Due to the unsuccessful nature of existing treatments which focus on the tumour cells, researchers are now examining the role played by the surrounding pancreatic stellate cells in the progression of this deadly disease.

Pancreatic cancer is the fourth leading cause of cancer death in men and women in western societies, and it has a 5-year survival rate of less than 5%. The poor prognosis of this disease is largely due to how it invades local tissues early and spreads far throughout the body.

As this cancer often presents at an advanced stage, only 10–20% of patients are suitable for surgical treatment. Chemotherapy drugs also have little if any success. With the treatment and outcome of pancreatic cancer not changing in more than 30 years, there is an urgent need for novel approaches to dealing with this disease.

In the past, the main research focus for pancreatic cancer has been on the tumour cells. In this study, researchers are examining the surrounding tissues in pancreatic cancer progression, and the stromal/desmoplastic cells which serve the cancer and help it to grow and spread. The identification of the cells responsible for this – pancreatic stellate cells – suggests that they influence local growth and distant spread of pancreatic cancer.

An improved understanding of the specific mechanisms involved in this interaction will help to create new ways to interrupt cancer development.


In 2011, the researchers built on their important discovery that human pancreatic stellate cells

accompany cancer cells when they move through the body and that these cells are more likely to migrate when in the presence of cancer cells.

Researchers treated mice with pancreatic cancer with an antibody that they thought may help prevent cancer cells communicating with healthy cells. This drug prevented a growth factor called HGF (which is produced by pancreatic stellate cells) from binding with pancreatic cancer cells. This significantly inhibited the spread of the cancer cells, reducing the size of the tumours.

This result proved growth factors play a role in mediating the interaction between tumour cells and the pancreatic stellate cells known to facilitate cancer progression. It also indicated pancreatic stellate cells help tumours to grow blood vessels, which are vital for continued tumour survival.

The research team is continuing detailed examinations of the link between pancreatic cancer cells and pancreatic stellate cells. They are planning further investigations within the growing field of cancer genetics to determine whether treatments can be personalised. Every cancer is different and it is unlikely that a single drug will work perfectly for every patient, so by determining the exact characteristics of a tumour, clinicians may be able to develop more tailored treatments.

What impact will it have?The research team has determined that pancreatic cancer cells use the normal cells around them to help them spread throughout the body. An improved understanding of the specific mechanisms involved in this interaction will enable researchers to develop new ways to interrupt cancer development that do not involve the same sorts of largely ineffective treatments currently being used. The new treatments may be less damaging to the body, as they will be specifically targeted at the particular cancer. The findings from this project may also be applicable to other cancers with similar prominent cellular elements, such as cancers of the breast and prostate.

Lead researcher: Professor Minoti Apte, Director, Pancreatic Research Group, School of Medical Sciences, University of New South Wales


Clearing the way for insightsProject: Cancer Council NSW’s CLEAR Study

Excessive sun exposure, smoking, alcohol and obesity are lifestyle factors which lead to over one-third of all cancers. The Cancer Lifestyle and Evaluation of Risk (CLEAR) Study is recruiting people with cancer, and their partners, to take part in a groundbreaking research project. The study aims to develop the most comprehensive database ever compiled on the lifestyle and genetic factors influencing cancer in the NSW community. Having such a database will enable scientists to rapidly understand how genes discovered in the laboratory affect real-life risks in the population.

A cancer diagnosis can be a life-changing experience, with more than 36,000 people in NSW receiving this distressing news each year.

The Cancer Lifestyle and Evaluation of Risk (CLEAR) Study is designed to develop a rapidly accessible bank of comprehensive information on the lifestyle and genetic factors that influence cancer in the NSW community. The CLEAR Study will compare people who have been diagnosed with cancer with those who have not had cancer at all. The study is expected to lead to a much better understanding of the causes of many cancer types and will therefore provide invaluable information for both prevention and treatment.

Participants in the study each complete an extensive questionnaire, covering a wide range of factors including migration, ethnicity, physical activity, alcohol consumption, smoking, occupation, screening behaviour, certain dietary patterns and reproductive history. Collecting this detailed information is vital to understanding the lifestyle and genetic factors influencing cancer risk. Participants are also invited to contribute blood samples for storage in a biological repository (our cancer biobank).

The size of the population group in NSW, together with the diversity of lifestyles and cultural backgrounds, provides a large and unique population to study – and this is expected to provide meaningful answers about the causes of cancer, and how these vary in different cultural groups. It will enable valuable insights into which gene/environment interactions are important, and whether they differ between various groups within the NSW community.

A valuable repository of data

After all the analytical processes have been completed, the data, together with the blood samples stored in our cancer biobank, will be made available to the international research community. CLEAR data and samples will be released in annual stages, starting in 2013. The information from the study will be highly valuable to cancer researchers. In time, it will represent one of the largest repositories of this type of data available to researchers anywhere in the world. The data collected so far covers many more people than previously studied in Australia.

When participant numbers reach 10,000, results for cancers of the bowel, prostate, breast, lung, melanoma and non-Hodgkin’s lymphoma will be available in large enough numbers to study. When participation reaches 25,000, sufficient information will be available to assess the effects of the various genetic and lifestyle factors on the risk of developing rarer cancers such as liver, thyroid, ovarian and pancreatic cancers.

Data collected from people with less common cancers may be included in collaborative studies with other research groups to help contribute to more rapid research outcomes.

22

Clearing the way for insights

What impact will it have?In time, the CLEAR Study will represent one of the largest repositories of its type available to researchers anywhere in the world. The outcomes from analyses of CLEAR data will inform public health decisions about how best to prevent cancer. Its detailed lifestyle information will also provide a better understanding of the multifactorial causes of cancer in NSW. The CLEAR Study will also support better decision-making and prediction of outcomes for governments and key health organisations.

Lead researcher: Associate Professor Freddy Sitas, Director, Cancer Research Division, Cancer Council NSW


Recently, the number of people participating in the information-gathering process for the CLEAR Study reached approximately 7,000.

Collaboration is an indispensable component of the CLEAR Study – two of the five chief investigators are from institutions outside Cancer Council NSW. Fifteen hospitals and clinical cancer registries, twenty collaborators, ten study staff and two advisers along with the chief investigators have been involved in collecting and processing the information from the study’s many participants.

In preparation for analysis to commence, the CLEAR Study will be requesting linkage of its data with the Central Cancer Registry in order to confirm diagnoses and dates of diagnosis of participants. The study researchers are preparing for release

of blood specimens for selected cancer research projects, and it is important that the verification of the quality of the specimens stored in our cancer biobank (which now holds over 200,000 samples of blood from various studies) is guaranteed.

A Biobank Stability Study is also well underway. This study will check the effects of time and temperature on the stability of blood samples collected according to the study protocols. The huge distances the blood samples must travel in NSW, and the variety of weather conditions under which they are collected, stored and transported, can make it challenging to maintain the same conditions for each sample. Unfortunately, there is very little literature available on stability of markers in bloods (biomarkers) collected for epidemiological purposes, so further investigation is needed in this area.

Cancer types collected in the CLEAR StudyCancer type Male Female TotalBreast 6 1,455 1,461Bowel and other digestive organs 577 426 1,003Prostate 907 0 907Blood-related cancers 235 219 454Uterus and ovary 0 324 324Melanoma and other skin 157 166 323Lung 109 140 249Bladder and kidney 104 62 166Mouth and pharynx 111 42 153Thyroid and other glands 27 109 136Eye, brain and central nervous system 41 29 70Mesothelial and soft tissue 26 30 56Bone and articular cartilage 23 14 37Ill-defined and unspecified cancers 17 18 35

Total cases 2,340 3,034 5,374People without cancer 771 855 1,626Total enrolled participants 3,111 3,889 7,000

Figures as at April 2012. Of these cases, 75% have provided blood samples.


Finding out more about the unknownProject: Research into the experiences and the support and information needs of people affected by cancer of unknown primary

Cancer Council NSW is conducting research to better understand the unique experiences and unmet support and information needs of people affected by cancer of unknown primary (CUP). The information gained from this research is being used to develop a suite of multimedia support and information resources.

Cancer of unknown primary (CUP) is a group of cancers characterised by evidence of metastatic disease where the location of the primary cancer cannot be identified, despite appropriate investigation. There are nearly 3,000 new cases of CUP diagnosed each year in Australia, and in NSW, this cancer accounts for approximately 4% of cancer diagnoses and 8% of cancer death. Unfortunately, survival rates are generally poor.

Although CUP is the eighth most common cancer type in Australia, there are still significant knowledge gaps about this cancer. This lack of knowledge extends to the impact of this diagnosis on patients, their carers and their families.

The aims of Cancer Council NSW’s Multimedia Cancer Support project for CUP are to research the experiences and the support and information needs of people with a diagnosis of CUP, their carers and their family members. The research will improve our understanding of how people with CUP are diagnosed and cared for; their symptoms, quality of life and psychosocial needs; the needs of their carers and their families; and how doctors and people with CUP communicate with each other. The findings of this work are being used to develop better support and information resources for people affected by a diagnosis of CUP.

What we have achieved this year

Throughout 2011, researchers have been undertaking the following aspects of the project:

Clinician surveys (research into the information provided by medical oncologists to patients and family members/carers about the diagnosis and various treatment options)

Patient/family/carer surveys (research into the patients’ and family members’/carers’ experiences, including how they learned about their diagnosis; what they understand about CUP; what they understand about the purpose of treatment; what they understand about various treatment options; whether they experienced any distress associated with learning about their diagnosis and making treatment decisions; and whether they felt they were able to access adequate information and emotional support)

Development of a suite of multimedia information and support resources, including:

– Understanding Cancer of Unknown Primary booklet

– Dedicated CUP webpage within Cancer Council NSW’s website

– Video resources with information about CUP and standard treatments.

What impact will it have?This research project has yielded rich information about the unique experiences of people affected by CUP and has provided valuable insights into the impact of this diagnosis and how best to support these patients, and their families and/or carers. By developing a multimedia information and support program, patients and their families and/or carers affected by CUP will be able to access more facts about the cancer and more support, to gain a greater understanding about the illness and its likely impact on their lives, regardless of where they live. Gathering detailed information from patients about their needs will ensure support materials are targeted to address the issues identified as important by those affected by CUP.

Research team: Gillian Batt, Cancer Information and Support Services, Cancer Council NSW, is the principal investigator. Cancer Council NSW’s CUP project team is Amelia Beaumont and Helen Gooden [with previous contributions by Angela Pearce and Melissa Pigot].

Research partners: Professor Sanchia Aranda, Cancer Institute NSW; Ms Jane Barrett, consumer representative; Ms Nadine Hackl, Cancer Institute NSW; Dr Chris Karapetis,Flinders Medical Centre, South Australia; Dr Sylvie Lambert, University of Newcastle; Dr Monica Robotin, Cancer Council NSW; Associate Professor Penelope Schofield, Peter MacCallum Cancer Centre, Victoria; Professor Martin Tattersall, University of Sydney; Dr Anna Ugalde, Peter MacCallum Cancer Centre, Victoria; and Dr Claire Vajdic, University of New South Wales

24

Finding out more about the unknown

Appendices

25

StaffOffice of the CEODr Andrew Penman AM Chief Executive Officer

Angela AstonManager, Office of the CEO

Antonia DykesExecutive Assistant

Research StrategyCatherine Holliday, BN, GDipNutr, MHSc, MHP Head, Research Strategy

Kate Whittaker, BHlthResearch Governance Officer

Sam Thorp, BCom/BSc(Hons)Research Communication and Community Engagement Officer

Jane BennettVolunteer

‘B Positive’ ProgramDr Monica Robotin, MBBS, FRACS, MBA, MIH, MAppEpid Medical Director

Mamta Porwal, BHMS, MPH Project Coordinator ‘B Positive’

Yumi Patton, MBiostat Research Assistant

Debbie Nguyen Hepatitis B Community Educator

Cancer Research DivisionA/Prof Freddy Sitas, BSc, MSc(Med), DPhil Director, Cancer Research Division

Naomi Crain, BA, AdvDipFamTh Executive Assistant to Director

Kate Christian, BSc Operations Manager

Prof Dianne O’Connell, BMaths(Hons 1), PhD Unit Manager and Senior Epidemiologist

A/Prof Karen Canfell, BE(Hons), DPhil Senior Research Fellow

Dr Carolyn Nickson, BA, GDipEpidBiostats, PhD Research Fellow

Dr David Smith, BA, MPH, PhD Research Fellow

Dr Marianne Weber, BA(Hons), PhD Research Fellow

Dr Xue Qin Yu, MPH, PhD Research Fellow

Megan Smith, BE, MPH(Merit) Program Manager

Rajah Supramaniam, BSc, MPH(Hons) Program Manager

Dr Michael Caruana, BSc, DPhil Post-doctoral Research Fellow

Visalini Nair-Shalliker, BSc(Hons), MSc, MPH, PhD Post-doctoral Research Fellow

Dr Jufang Shi, MD, MPH, PhD Post-doctoral Research Fellow

Kate Simms, BSc(Hons), PhD Post-doctoral Research Fellow

Dr Louiza Velentzis, BSc(Hons), MSc, PhD Post-doctoral Research Fellow

Statisticians

Albert Bang, BCom

Sam Egger, BSc, MBiostat

Alison Gibberd, BSc(Hons), MStats

David Goldsbury, BSc(Hons), MPH(Merit)

Qingwei Luo, BSc, MAppStats

Project Coordinators

Katie Armstrong, BAppSc(HIM)

Kate Blacker, BSc(Nurs)

Leighna Carmichael, BA, MSc

Jessica Darlington-Brown, BSc(Population Health), MPH

Alicia Delgado, BA, MSW(Hons) (maternity leave)

Verity Hodgkinson, BSc, MSciMan

Suzanne Hughes, BSc(Hons), MNutrDiet

Clare Kahn, BMus(Hons), MMus(Perf)

Michael Revius, BSc

Jenny Rodger, BA(Hons), MSc

Leonardo Simonella, BA, MPH(Hons)

Cat Van Kemenade, MSc(HumMovSc), MPH

26

Staff

Data Manager

Johnson Yuan, BSc, BEd(Teach)

Research Programmers

Jie Bin Lew, BSc(Bioinformatics)

Robert Walker, BSc

Ming Xu, BEng(Mech)(Biomed), BMedSci

Lab Manager

Janis Jansons, BSc, MSc

Aboriginal Community Liaison Officer

Veronica Saunders

Senior Research Assistants

Christina Christou, BHS, MPH, DipNat

Kristie Weir, BSc(Population Health)

Laboratory Research Assistants

Mahboobeh Hosseini, BSc

Smitha Rajpattan, BPharm, MAppSc

Sarita Tiwari, MAppSc, MOBT, DMLT

Research Assistants

Maria Albania, BSc/BEd

Karen Allison, BBehavHlthSc

Moa Aye, MBBS, MPH

May Chiew, BPharm, MPH(Professional Practice)

Bonnie Nixon, BMedSc

Susan Spratley, BPsych(Hons)

Administration

Pinya Leeder, BA, MProfAcct

Kimberley McGregor

Elle McGlynn, BA

Postgraduate Students

Nayyereh Aminisani, BSc(Nurs), MSc(Epid), (PhD candidate)

Yoon-Jung Kang, BA, MPH(Hons), (PhD candidate)

Qingwei Luo, BSc, MAppStats, (PhD candidate)

Usha Salagame, BSc(Microbiol), PostgradCertBioinformatics, MSc(Biotech), (PhD candidate)

Leonardo Simonella, BA, MPH, (PhD candidate)

Maria Albania, BSc/BEd, (MBiostats candidate)

Albert Bang, BCom, (MBiostats candidate)

May Chiew, BPharm, (MPH(Professional Practice) candidate)

Jie Bin Lew, BSc(Bioinformatics), (MPH candidate)

Simon Willcox, BCom(Marketing), (MPH(Hons) candidate)


GrantsGrants awarded to CCNSW

‘B Positive’ ProgramRobotin M, Porwal M, Penman A. Preventing hepatocellular cancer through optimising the detection and management of chronic hepatitis B in primary care. NSW Ministry of Health Grant. 2011-2013. $183,400

Robotin M, Porwal M, Strasser S, George J. Learning about health disparities using a service-learning educational model for chronic hepatitis B management in migrant populations. University of Sydney Strategic Teaching Enhancement Projects Grant Scheme. 2011. $35,000

Cancer Research DivisionNew grants in 2011

Canfell K. Evaluation of future cervical cancer prevention strategies in Australia. NHMRC Career Development Award. 2011-2014. $384,160

Canfell K. Evaluation of the cost-effectiveness of colorectal cancer screening in Australia. Cancer Council NSW (internal grant via Health Strategies Division). 2011-2012. $200,000

Canfell K, Clements M, Nickson C, Brotherton J, Castle P, Schiffman M, Lord S, Shi JF. Evaluation of primary HPV testing for cervical screening in Australia. NHMRC Project Grant. 2011-2013. $677,522

Canfell K, Smith M, Walker R. Analytical services for National Cervical Screening Program Monitoring Reports. National Screening Unit, New Zealand Ministry of Health. 2011-2014.

Chambers S, Baade P, Youl P, Aitken J, Dunn J, Garvey G, Valery P, O’Connell D. The effects of stigma and nihilistic views on lung cancer outcomes. Cancer Australia Request For Tender. 2011-2012. $588,112

Chambers SK, Smith D, Berry M, Lepore S, Foley E, Occhipinti S, Frydenberg M, Gardiner RA. A randomised controlled trial of mindfulness intervention for men with advanced prostate cancer. Cancer Australia; Griffith University. 2011. $570,650

Clements M, Smith D, O’Connell D, Etzioni R, Gardiner R. Testing and treatment for prostate cancer in Australia: epidemiology and modelling. NHMRC Project Grant. 2011-2013. $518,390

Haines M, O’Connell D, Young J, Smith D, Kneebone A, Brooks A, Watt H. Improving evidence-based care for locally advanced prostate cancer: a randomised phased trial of clinical guideline implementation through a clinical network. NHMRC Partnership Project Grant. 2011-2013. $533,442 (NHMRC); $537,674 (PCFA)

Ingham J, O’Connell D, Phillips J, Davidson P, Girgis A, Wilkinson A, Piza M, Pigot M, Goldsbury D. Last days of life linkage study: patterns of health services use and experiences of adult NSW residents in the year prior to death from illness. Cancer Institute NSW. 2011-2012. $83,748.

Nair-Shalliker V. Prostate Cancer Foundation of Australia Conference Travel Grant. 2011. $500

O’Connell D, Supramaniam R, Dillon A, Ingham J, Fernando P. Cancer comorbidity, treatment, survival and end-of-life care for Aboriginal people in NSW. Cancer Institute NSW. 2011-2013. $280,688

Shi JF. International Papillomavirus Society Travel Grant for 27th International Papillomavirus Conference and Workshops (IPV2011). 2011. $1,000

Smith D. ANZUP/Novartis Conference Travel Grant. 2011. $1,000

Smith D. Prostate Cancer Foundation of Australia Conference Travel Grant. 2011. $500

Continuing grants in 2011

Canfell K. MAVARIC: economic evaluation of manual vs. automated cytology in the UK. UK National Health Service Cervical Screening Program. 2009-2011.

Neale R, O’Connell D, Janda M, Merrett N, Goldstein D, Beesley V, Wyld D, Gooden H. Patterns of care and quality of life in patients with pancreatic cancer. NHMRC Project Grant. 2010-2012. $655,213

O’Connell D, Butow P, Armstrong B, Treloar C, Knight R, Dillon A, Newman C, Supramaniam R. Patterns of cancer care for Indigenous people in NSW. NHMRC Health Services Research Grant. 2007-2013. $1,580,755

O’Connell D, Chambers S, Moxey A, Smith DP. Use of complementary and lifestyle therapies by men with prostate cancer: a population-based study. Prostate Cancer Foundation of Australia. 2009-2011. $137,766

Shi J, (Supervisor Canfell K). Cost-effectiveness evaluation of cervical cancer prevention strategies in China. American Cancer Society International Fellowships for Beginning Investigators, UICC/ACSBI Fellowship. 2009-2011.

Sitas F, Armstrong B, Banks E, Kricker A, Weber M, Pawlita M. Infectious and lifestyle determinants of non-melanoma skin cancer. NHMRC Project Grant. 2009-2011. $953,200

Sitas F, Canfell K, O’Connell D, Banks E, Ward R, Baron M. The NSW Cancer Lifestyle and Evaluation of Risk (CLEAR) study. Cancer Council NSW. 2006-2011. $2,500,000

Yu XQ. Projecting prevalence by phase of care for colorectal, lung, breast and prostate cancer in New South Wales. NHMRC Fellowship. 2009-2012. $279,000

28

Grants

Health Strategies DivisionBaur L, Bauman A, Kelly B, Chapman K, Smith B. Food and drink company sponsorship of children’s sport: publicity or philanthropy? Australian Research Council Linkage Grant. 2009-2011. $290,500

Pettigrew S, Quester P, Chapman K, Miller C. Investigating the indirect effects of child-targeted food promotion. Australian Research Council Linkage Grant. 2010-2011. $105,750

Grants awarded by CCNSWNew Program Grants in 2011

Hogg P, Dilda P. Metabolism inhibitors for the treatment of brain and pancreatic cancer. University of New South Wales. 2011-2015. $2,250,000

Norris M, Haber M, Marshall G, Kavallaris M. Towards cure of childhood ALL: improved diagnostics, therapeutics and prevention strategies. Children’s Cancer Institute Australia for Medical Research. 2011-2015. $2,250,000

Ormandy C, Carroll J, Kaplan W, Lakhani S, Naylor M, Swarbrick A. Personalising breast cancer management by discovering the transcriptional basis for tumour phenotype. Garvan Institute of Medical Research. 2011-2015. $2,249,976

Reddel R. Alternative lengthening of telomeres: from basic biology to drug discovery. Children’s Medical Research Institute. 2011-2012. $2,250,000

Continuing Program Grant in 2011

Horvath L, Ackland S, Balleine R, Biankin A, Catchpoole D, Clarke S, deFazio A, Gurney H, Links M, Mann G, Moscato P, Murray M, Nath C, Richardson D, Scott R. Building capacity in pharmacogenomics across NSW: PRIMe (Pharmacogenomic Research for Individualised Medicine). Garvan Institute of Medical Research. 2010-2015 $300,000

New Strategic Research Partnership (STREP) grants in 2011

Biankin A, Grimmond S, Apte M, Goldstein D, Clarke S, Kench J, Gill A, Samra J, Gebski V, Wu J, Med S, Horvath L. Genotype-guided cancer therapy (genomics theranostics). Garvan Institute of Medical Research. 2011-2015. $1,500,000

Sanson-Fisher R. Behavioural Science Strategic Research Partnership. University of Newcastle. 2011-2014. $1,200,000

Continuing Strategic Research Partnership (STREP) grants in 2011

George J, McCaughan G, Dore G, Liddle C, Strasser S. Epidemiology, prevention and management of liver cancer in NSW: towards a strategic research partnership. University of Sydney. 2008-2012. $250,000

Nowak A, McDonald K, Teo C, Wheeler H, Joseph D, Robinson B. Clinical Outcomes and Genetic Epidemiology of high grade Glioma: COGEG. University of Western Australia. 2008-2012. $247,029

Whiteman D, Lord R, Watson D, Phillips W, Hayward N. PROBE-NET: Progression of Barrett’s Esophagus to Cancer Network. Queensland Institute of Medical Research. 2008-2012. $189,757

New Research Project Grants in 2011

Baxter R. Targeting IGFBP-3 signalling pathways as a novel therapeutic approach in triple-negative breast cancer. University of Sydney. 2011-2013. $119,659

Bryan T. G-quadruplex stabilisers as cancer therapeutics. University of Sydney. 2011-2013. $97,508

Chircop M, Sakoff J, McCluskey A, Jones N. Dynamin as a new drug target for the treatment of glioblastoma. University of Sydney. 2011-2013. $120,000

Greer P, Denham J, Dowling J, Salvado O. Does the initial treatment plan predict doses delivered to normal tissues during prostate radiation therapy? Calvary Mater Newcastle Hospital. 2011-2013. $116,598

Henderson B, Brocardo M, Molloy M. Regulation of APC intracellular dynamics and function. Westmead Millennium Institute for Medical Research. 2011-2013. $120,000

Howell V, Gill A. New opportunities for the study of ovarian cancer through characterisation of mouse models. University of Sydney. 2011-2013. $97,508

Lock R, Kaplan W, Carol H. Predicting the in vivo sensitivity of paediatric acute lymphoblastic leukaemia to BH3-mimetic drugs. Children’s Cancer Institute Australia for Medical Research. 2011-2013. $109,750

Lui T, Zhang Y, Pasquier E. The critical role of the histone demethylase JMJD1A in cancer. University of New South Wales. 2011-2013. $110,250

MacKenzie K, Fletcher J. The prognostic and therapeutic significance of dyskerin and telomerase enzyme activity in neuroblastoma. University of New South Wales. 2011-2013. $117,508

Macrae F, Boussioutas A, Clarke J, Topping D, Toden S, Lynch P, Spigelman A, Appleyard M, Hollington P, Ee H, Cameron D. The effects of butyrylated high-amylose maize starch on polyposis in FAP volunteers. Royal Melbourne Hospital. 2011-2013. $119,489

Rasko J, Bailey C. Dissecting the multi-component machine that controls chromatin architecture. Centenary Institute. 2011-2013. $119,658


Rasko J, Ritchie W, Holst J. The role of small non-coding RNAs (sncRNAs) in alternative splicing. Centenary Institute. 2011-2013. $120,000

Vial P, Kuncic Z, Greer P, Baldock C, Holloway L, Barton M. A next-generation detector for radiotherapy treatment verification with dual capability for simultaneous imaging and dosimetry. South Western Sydney Local Health District. 2011-2013. $115,375

Ward R. Role of dietary compounds on PGC-1 alpha methylation in colorectal cancer. University of New South Wales. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. 2011-2013. $107,087

Ward R, Bourke M, Hawkins N. Laterally spreading tumours of the colorectum: an alternative pathway of colorectal cancer development in the Western world. University of New South Wales. 2011-2013. $120,000

Zhang X, Yang M. Targeting pro-survival mechanisms to sensitise human melanoma to immunotherapy. University of Newcastle. 2011-2013. $119,750

Continuing Research Project Grants in 2011

Baker M, Nice E. A colorectal cancer ‘interactome’ paradigm that influences patient survival. Macquarie University. CCNSW Project Grant. 2010-2012. $100,000

Bendall L, Juarez J. The role of sphingosine-1-phosphate in haematopoietic stem cell egress from the bone marrow. University of Sydney. CCNSW Project Grant. 2010-2012. $120,000

Bryan T, Cohen, S. Recruitment of human telomerase to telomeres. University of Sydney. CCNSW Project Grant. 2010-2012. $116,250

deFazio A. Pathways of malignant progression in ovarian cancer. University of Sydney. CCNSW Project Grant. 2010-2012. $119,075

Greer P. Real-time dose monitoring for patient safety in radiation therapy. University of Newcastle. CCNSW Project Grant. 2010-2012. $120,000

Kohonen-Corish M, Pangon L, Musgrove E. Functional characterisation of the putative tumour suppressor gene MCC in colorectal cancer. Garvan Institute of Medical Research. CCNSW Project Grant. 2010-2012. $120,000

Liu T, Bedalov A, Scarlett C. Targeting Myc onco-protein degradation for the treatment of Myc-induced malignancies. University of New South Wales. CCNSW Project Grant. 2010-2012. $106,500

Lyons G, Halliday G. Restoring epithelial differentiation to squamous cell carcinomas. University of Sydney. CCNSW Project Grant. 2010-2012. $120,000

Meiser B. Too much, too soon? The impact of treatment-focused genetic testing in patients newly diagnosed with breast cancer. University of New South Wales. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. 2010-2012. $21,149

Ashman L, Verrrills N, Denham J. Tetraspanin proteins in prostate cancer progression and prognosis. University of Newcastle. CCNSW Project Grant. 2009-2011. $119,000

Bebawy M, Grau G, Combes V. Microparticle-mediated transfer of P-glycoprotein in conferring multidrug resistance in cancer. University of Sydney. CCNSW Project Grant. 2009-2011. $118,375

Byrne J, Bright R, Catchpoole D, Smith B. The molecular basis of cell transformation produced by TPD52 overexpression. University of Sydney. CCNSW Project Grant. 2009-2011. $94,750

Chen S, Slavin M, Szer J, Bardy P, Sorrell T, Schwarer A, Morrissey O. Randomised trial of diagnostic strategies for invasive aspergillosis in at-risk haematology patients: funding extension. Westmead Hospital. CCNSW Project Grant. 2009-2011. $71,875

Daly R, Ormandy C. Tyrosine kinase profiling of human basal breast cancers. Garvan Institute of Medical Research. CCNSW Project Grant. 2009-2011. $119,250

Fabbro M, Sakoff J. Dynamin inhibitors as new anti-cancer drugs. University of Sydney. CCNSW Project Grant. 2009-2011. $118,500

Goldstein D, Spry N, Padbury R, Shannon J, Biankin A, Kneebone A, Fitzgerald P. LAP07: randomised multicentre phase III study in patients with locally advanced adenocarinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib. University of Sydney. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. 2009-2012. $26,967

Gottlieb D, Clancy L. Adoptive immunotherapy for the prevention of varicella-zoster virus reactivation post–stem cell transplant. University of Sydney. CCNSW Project Grant. 2009-2011. $99,750

Haass N. The role of melanoma stem cells in melanomagenesis. Centenary Institute. CCNSW Project Grant. 2009-2011. $120,000

Hart D, Radford K. RNA loading of tumour-associated antigens and the activation of blood dendritic cells for prostate cancer immunotherapy. University of Queensland. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. 2009-2012. $30,970

Haydon A, Zalcberg J, Walpole E, Yip D, Price T, Howard K. SCOT: Short Course Oncology Therapy. A study of adjuvant chemotherapy in colorectal cancer. Monash University. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. 2009-2012. $31,213

30

Grants

Jolly C, McKay M, Manis J, Xu H. Understanding AID-induced cancer: unravelling complex mutation and repair pathways. University of Sydney. CCNSW Project Grant. 2009-2011. $120,000

Leong T, Gebski V, Smithers B, Watson D, Spry N, Zalcberg J. Randomised phase II/III study of preoperative chemoradiotherapy versus chemotherapy for resectable gastric cancer. University of Sydney. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. 2009-2012. $5,773

McDonald K, Bennett M, Davey R, Robinson B. The role of IQGAP1 in actively migrating glioma cells and its regulation by miR-124. University of Sydney. CCNSW Project Grant. 2009-2011. $119,750

Murray M, Gurney H, McLachlan A. Development of personalised dosage protocols for tyrosine kinase inhibitors in oncology patients. University of Sydney. CCNSW Project Grant. 2009-2011 $95,550

Naylor M. Role of beta1 integrin in prostate development and carcinogenesis. Garvan Institute of Medical Research. CCNSW Project Grant. 2009-2011 $120,000

O’Neill G, Golemis E. The signalling switch function of the pro-metastatic, adhesion adaptor protein HEF1. University of Sydney. CCNSW Project Grant. 2009-2011. $120,000

Poulsen M, Veness M, Rischin D, Macfarlane D. Phase II efficacy study of chemoradiotherapy in PET-staged II-III merkel cell carcinoma of the skin. Princess Alexandra Hospital. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. 2009-2012. $9,631

Tangye S, Palendira U. EBV-specific CD8+ T cells in anti-tumour immune responses in patients predisposed to developing lymphoma. Garvan Institute of Medical Research. CCNSW Project Grant. 2009-2011. $120,000

Williams M, Metcalfe P, Bailey M, Rozenfeld A, Forstner D, Everitt C. A dosimetric Inter-Comparison of Australian Radiotherapy IMRT Systems (ICARIS). University of Wollongong. CCNSW Project Grant. 2009-2011. $68,625

Young J, Solomon M, Frizelle F, Heriot A, King M, Salkeld G. Quality of life outcomes and cost-effectiveness of pelvic exenteration for people with advanced rectal cancer. University of Sydney. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. 2009-2012. $20,046

Zhang ZD, Avery-Kiejda K, Hersey P. Targeting p53 isoforms, 40p53 and p53ß, to promote chemosensitivity in human melanoma. University of Newcastle. CCNSW Project Grant. 2009-2011 $119,000

Innovator Grants

Don A. Developing sphingosine kinase 2 inhibitors to block glioblastoma cell proliferation. University of New South Wales. 2011-2012. $8,648

George J, Hebbard L. Novel molecular targets for treatment of hepatocellular cancer (HCC). University of Sydney. 2011-2012. $100,000

Grau G, Suter C. Deep sequencing of glioma-derived microparticles. University of Sydney. 2011-2012. $100,000

Murray M. Pharmacogenomic approaches to minimise sorafenib toxicity in patients with liver cancer. University of Sydney. 2011-2012. $97,730

Phillips W. Using familial genetics to identify genes involved in the biology of Barrett’s oesophagus. Peter MacCallum Cancer Centre. 2011-2012. $100,000

Shackel N. Discovering novel non-invasive diagnostic and prognostic markers in hepatocellular carcinoma. University of Sydney. 2011-2012. $100,000

Thompson S. Sentinel lymph node biopsy in oesophageal adenocarcinoma – improving staging accuracy and optimising treatment. The Royal Adelaide Hospital. 2011-2012. $94,255

Willowson K. The role of imageable microspheres in radioembolisation treatment planning for HCC. University of Sydney. 2011-2012. $3,217

Research programs

Biankin A. International Cancer Genome Consortium. Garvan Institute of Medical Research. $500,000

Cancer Trials NSW, in partnership with Cancer Institute NSW. $600,000

45 and Up Cohort Study. Sax Institute. $300,000

Commissioned research projects

Bonevski B. Consumer understanding of vitamin D messages. University of Newcastle. 2011. $39,452

Burton S, Spanjaard D. An investigation of the impact of retail distribution on tobacco purchase and smoking, and on high-kilojoule food purchases. University of Western Sydney. 2011-2012. $75,951

Currie G, Wheat J, Kiat H. Novel approach to MRI-based molecular imaging: proof of concept. Macquarie University. 2011. $56,080

Sanson-Fisher R. Cancer survival study. University of Newcastle. 2011. $70,000

Whiteman D. PROBE-NET centres of research excellence: proposal development grant. Queensland Institute of Medical Research. 2011. $5,000

Clinical Trials Protocol Grant

Lord RV, Bourke M, Watson D. Randomised trial of endoscopic radiofrequency ablation versus complete mucosectomy with stent for Barrett’s high-grade dysplasia or intramucosal adenocarcinoma. St Vincent’s Centre for Applied Medical Research; University of New South Wales. 2011-2012. $50,000


‘B Positive’ ProgramPublications

Macartney KK, Porwal M, Dalton D, Cripps T, Maldigri T, Isaacs D, Kesson A. Decline in rotavirus hospitalisations following introduction of Australia’s national rotavirus immunisation program. J Paediatr Child Health. 2011;47(5):266-70. DOI:10.1111/j.1440-1754.2010.01953.x. Epub 2011 Jan 18.

Robotin M. Botanical products in the 21st century: from whence to whither. Cancer Forum. 2011;35(1):6-9.

Robotin M. From traditional medicines to drug discovery. In: Olver I, Robotin M, editors. Perspectives on complementary and alternative medicine. Singapore: Imperial College Press; 2011. p.157-186.

Robotin M. Hepatitis B prevention and control: lessons from the East and the West. World J Hepatol. 2011;3(2):31-7. [editorial]

Presentations

Porwal M, Brooke M, Nguyen D, Robotin M. Understanding the key drivers impacting chronic hepatitis B screening in south-western Sydney – proposal for community engagement framework. Presentation at: National Hepatitis Health Promotion Conference; 2011 Nov 24-25; Brisbane, Australia.

Robotin M. Community-based strategies to increase hepatitis B awareness and testing in migrant communities. Presentation at: Fairfield Migrant Resource Centre; 2011 Aug 30; Cabramatta, Australia.

Robotin M. Hepatitis B and liver cancer. Health professional talk at: Cancer Council Western Australia; 2011 Aug 22; Perth, Australia.

Robotin M. Hepatitis B and liver cancer: what is the link? Presentation at: public forum, Perth Library; 2011 Aug 22; Perth, Australia.

Robotin M. Hepatitis B, hepatocellular cancer and the ‘B Positive’ project. Presentation at: Public Health Professionals CME Meeting; 2011 Aug 23; Albany, Australia.

Robotin M. Hepatitis B infection and health inequalities in migrant populations in Australia. Presentation at: Fairfield Migrant Interagency Forum, Fairfield City; 2011 Jul 15; Sydney, Australia.

Robotin M. Hepatitis, liver cancer and the ‘B Positive’ Program. Address to: Hepatitis Australia Board; 2011 Sep 14; Sydney, Australia.

Robotin M, Patton Y, Kansil M , Penman A , George J. The costs of treating chronic hepatitis in Asian populations – a comparison of current treatment guidelines. Presentation at: Asia Pacific Association for the Study of the Liver (APASL) 2nd Hepatocellular Carcinoma Conference; 2011 Dec 1-3; Jeju Island, Republic of Korea.

Robotin M, Porwal M, Prado S. Engaging communities in the fight to address health disparities: the case of hepatitis B. Presentation at: Federation of Ethnic Communities’ Councils of Australia (FECCA) Conference (Advancing Multiculturalism); 2011 Nov 18; Adelaide, Australia.

Posters

Liu Y, Robotin M. Evaluating the impact of research: a bibliometric analysis of research by Cancer Council NSW. Poster presented at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Nguyen D, Porwal M, Robotin M. Engaging with Vietnamese communities in the fight against hepatitis B–related liver cancer. Poster presented at: National Hepatitis Health Promotion Conference; 2011 Nov 24-25; Brisbane, Australia.

Patton Y, Porwal M, George J, Penman AG, Robotin M. Developing a chronic hepatitis B disease registry to prevent hepatocellular carcinoma in NSW. Poster presented at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Porwal M, Robotin M. Community-based interventions raising awareness and promoting screening for chronic hepatitis B in CALD communities. Poster presented at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Robotin M, Holliday C, George J, Enright C, Penman A. Defining a research agenda for liver cancer in Australia – the role of the not-for-profit cancer control organisations. Poster presented at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Robotin M, Patton Y, Putha V, George J. Population-level prevention of hepatitis B–related HCC in Australia – the primary care perspective. Poster presented at: Asia Pacific Association for the Study of the Liver (APASL) Conference; 2011 Feb 17-20; Bangkok, Thailand.

Publications, presentations and posters

32


Cancer Research DivisionPublications

Aminisani N. Cervical screening in New South Wales and its relationship to country of birth and socioeconomic status. PhD [thesis]. Sydney: University of Sydney; 2011.

Canfell K, Lew JB, Smith M, Walker R. Cost-effectiveness modelling beyond MAVARIC study end-points. In: Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, Legood R, Gray A, Sadique Z, Moss S, on behalf of the MAVARIC Trial Study Group. MAVARIC – a comparison of automation-assisted and manual cervical screening: a randomised controlled trial. Health Technol Assess. 2011;15(3).

Canfell K, Lew JB, Smith M, Walker R. Modelling HPV test of cure. In: Moss S, Kelly R, Legood R, Sadique Z, Canfell K, Lew JB, Smith M, Walker R. Evaluation of sentinel sites for HPV triage and test of cure. Report to the NHS Cancer Screening Programs. UK; September 2011.

Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, Chen JF, Legood R, Smith MA, Nickson C, Qiao YL. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine. 2011;29:2487-94.

Carless PA, Rubens FD, Anthony DM, O’Connell D, Henry DA. Platelet-rich-plasmapheresis for minimising perioperative allogenic blood transfusion. Cochrane Database Syst Rev. 2011;(3):CD004172. DOI:10.1002/14651858.CD004172.pub2.

Chambers SK, Pinnock C, Lepore SJ, Hughes S, O’Connell DL. A systematic review of psychosocial interventions for men with prostate cancer and their partners. Patient Educ Couns. 2011;85:e75-e88.

Fry SA, Afrough B, Lomax-Browne HJ, Timms JF, Velentzis LS, Leathem AJ. Lectin microarray profiling of metastatic breast cancers. Glycobiology. 2011;21:1060-70.

Goldsbury DE, Smith DP, Armstrong BK, O’Connell DL. Using linked routinely collected health data to describe prostate cancer treatment in New South Wales, Australia: a validation study. BMC Health Serv Res. 2011;11:253.

Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V, Million Women Study Collaborators (including Canfell K). Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011;12:785-94.

Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;(1):CD001886. Epub 2011 Jan 19.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (including Sitas F). The evaluation of carcinogenic risks to humans [IARC monographs]. Vol. 100, A review of human carcinogens. Part B, Biological agents. Lyon, France: World Health Organisation International Agency for Research on Cancer; 2011.

Jemal A, Thun M, Yu XQ, Hartman AM, Cokkinides V, Center MM, Ross H, Ward EM. Changes in smoking prevalence among US adults by state and region: estimates from the Tobacco Use Supplement to the Current Population Survey, 1992-2007. BMC Public Health. 2011;11:512.

Salagame U, Canfell K, Banks E. An epidemiological overview of the relationship between hormone replacement therapy and breast cancer. Expert Rev Endocrinol Metab. 2011;6:397-409.

Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer. 2012;130(3):641-52. DOI: 10.1002/ijc.26042. Epub 2011 Jun 10.

Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, Simonella L, Ma L, Kang YJ, Zhang YZ, Smith MA, Chen JF, Feng XX, Qiao YL. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer. 2011;11:239.

Sitas F, Yu XQ, O’Connell D, Blizzard L, Otahal P, Newman L, Venn A. The relationship between basal and squamous cell skin cancer and smoking-related cancers. BMC Res Notes. 2011;4:556.

Smith M, Canfell K. Cervical Screening in New Zealand: Independent Monitoring Annual Report (2008-2009). Commissioned report for National Cervical Screening Program Advisory Group. Wellington, New Zealand; 2011.

Smith M, Canfell K. Cervical screening in New Zealand: Independent Monitoring Report 33 (January-June 2010). Commissioned report for National Cervical Screening Program Advisory Group. Wellington, New Zealand; 2011.

Smith M, Canfell K. Cervical Screening in New Zealand: Independent Monitoring Report 34 (July-December 2010). Commissioned report for National Cervical Screening Program Advisory Group. Wellington, New Zealand; 2011.


Smith M, Canfell K. Cervical Screening in New Zealand: Independent Monitoring Report 35 (January-June 2011). Commissioned report for National Cervical Screening Program Advisory Group. Wellington, New Zealand; 2011.

Smith M, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine. 2011;29:9112-22.

Smith M, Walker R, Clements M, Canfell K. Independent Monitoring Report for July-December 2008: National Cervical Screening Program. Report to the NZ National Screening Unit. National Screening Unit: New Zealand; March 2011.

Smith M, Walker R, Clements M, Canfell K. Independent Monitoring Report for January-June 2009: National Cervical Screening Program. Report to the NZ National Screening Unit. National Screening Unit: New Zealand; March 2011.

Smith M, Walker R, Clements M, Canfell K. Independent Monitoring Report for July-December 2009: National Cervical Screening Program. Report to the NZ National Screening Unit. National Screening Unit: New Zealand; March 2011.

Velentzis LS, Keshtgar MR, Woodside JV, Leathem AJ, Titcomb A, Perkins KA, Mazurowska M, Anderson V, Wardell K, Cantwell MM. Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res Treat. 2011;128:473-82.

Wang SM, Shi JF, Kang DJ, Song P, Qiao YL. Impact of human papillomavirus–related lesions on quality of life: a multicentre hospital-based study of women in Mainland China. Int J Gynecol Cancer. 2011;21:182-8.

Wang W, O’Connell D, Stuart K, Boyages J. Analysis of 10-year cause-specific mortality of patients with breast cancer treated in New South Wales in 1995. J Med Imaging Radiat Oncol. 2011;55:516-25.

Weber MF, Banks E, Sitas F. Smoking in migrants in New South Wales, Australia: report on data from over 100,000 participants in the 45 and Up Study. Drug Alcohol Rev. 2011;30:597-605.

Willcox S. What do cancer patients and their partners believe causes cancer? Master of Public Health Honours [thesis]. Sydney: University of Sydney; 2011.

Willcox SJ, Stewart BW, Sitas F. What factors do cancer patients believe contribute to the development of their cancer? (New South Wales, Australia). Cancer Causes Control. 2011;22:1503-11.

Xiang W, Shi JF, Li P, Wang JB, Xu LN, Wei WQ, Zhao FH, Qiao YL, Boffetta P. Estimation of cancer cases and deaths attributable to infection in China. Cancer Causes Control. 2011;22:1153-61.

Yu XQ, Smith DP, Clements MS, Patel MI, McHugh B, O’Connell DL. Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study. BMJ Open. 2011;1(1):e000104. Epub 2011 Apr 7.

Presentations

Canfell K. Challenges in evaluating new strategies for cervical cancer prevention: integrating cervical screening and HPV vaccination. Presentation at: Health Economics Collaboration Seminar Series; 2011 May; Sydney, Australia.

Canfell K. COMPASS: a randomised controlled trial of primary HPV testing in Australia. Presentation at: Preventing Cervical Cancer Conference (PCC) 2011; 2011 Nov 9-11; Melbourne, Australia.

Canfell K. Evaluation of cervical cancer prevention in China. Presentation at: Preventing Cervical Cancer Conference (PCC) 2011; 2011 Nov 9-11; Melbourne, Australia.

Canfell K. Evaluation of the cost-effectiveness of primary HPV testing in urban populations in China. Presentation at: 27th International Papillomavirus Conference and Clinical and Public Health Workshops; 2011 Sep 16-22; Berlin, Germany.

Canfell K. Pap smears versus HPV screening. Presentation at: 6th Annual Family Planning NSW Conference; 2011 Aug 20; Sydney, Australia.

Canfell K. What evidence base would be required for a transition to primary HPV screening in Australia? Presentation at: Symposium on Cytology vs. Primary HPV Screening, held at Cancer Council NSW; 2011 Nov; Sydney, Australia.

Canfell K, Lew JB, Howard K, Gertig D, Smith M, Nickson C, Shi JF, Dyer S, Lord S, Tan J. Cervical screening expenditure in Australian women targeted for HPV vaccination. Presentation at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Canfell K, Shi JF, Lew JB, Walker R, Smith M, Nickson C, Qiao Y. Predicted long-term outcomes after single-round HPV screening in rural China. Presentation at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Carmichael LK, Goldsbury DE, Smith DP, Gattellari M, Chambers S, Slevin TJ, O’Connell D L. Who are the men aged over 75 who are having PSA tests? Presentation at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia. [Nominated for Best of the Best Oral Presentation – Urology]

Chiew M. Social isolation among older Australian smokers: 45 and Up. Presentation at: Annual 45 and Up Study Collaborators Meeting; 2011 Sep; Sydney, Australia.

34


Darlington-Brown J. Cervical Health Study. Presentation at: NSW Pap Test Register; 2011 Dec; Sydney, Australia.

Darlington-Brown J, Christian K, Smith D, Revius M, Canfell K, O’Connell D. Career progression within Cancer Council. Presentation at: NSW & ACT Cancer Epidemiology Network Meeting; 2011 Dec; Sydney, Australia.

Goldsbury D. The Colorectal Cancer Referral Pathways Study: 45 and Up Study. Presentation at: Annual 45 and Up Study Collaborators Meeting; 2011 Sep; Sydney, Australia.

Hodgkinson V. Skin Health Study: challenges in data collection: 45 and Up Study. Presentation at: Annual 45 and Up Study Collaborators Meeting; 2011 Sep; Sydney, Australia.

Luo Q, O’Connell D, Smith D, Yu XQ. Characteristics of men with unstaged prostate cancer: analysis of NSW Central Cancer Registry data. Presentation at: Early Career Researcher Award presentation, NSW & ACT Cancer Epidemiology Network Meeting; 2011 Dec; Sydney, Australia.

Nair-Shalliker V. Sun exposure and prostate cancer risk in New South Wales, Australia. Presentation at: Annual General Meeting of the Australasian Epidemiological Association; 2011 Nov; Perth, Australia.

Nickson C, Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S, Lord S, Canfell K. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. Presentation at: Annual General Meeting of the Australasian Epidemiological Association; 2011 Nov; Perth, Australia.

Pascoe SW, Harris MF, O’Connell DL, Veitch C, Beilby JJ, Spigelman AD, Goldsbury D, Barton MB, Olver I, Crossland L, Stubbs J. The Colorectal Cancer Referral Pathways Project: findings from record linkage, audit of referral letters and focus groups. Presentation at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia. [Nominated for Best of the Best Oral Presentation – Primary Care]

Shi JF, Canfell K, Lew JB, Ma L, Walker R, Zhao F, Smith M, Chen J, Qiao Y. Cost-effectiveness of primary HPV screening in urban populations in China. Presentation at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, O’Connell DL, Whiteman DC, Brennan P, Malekzadeh R, Pawlita M, Dawsey SM, Waterboer T, Webb PM, Green AC, Hayward NK, Zaridze D, Holcatova I, Mates D, Szeszenia-Dabrowska N, Ferro G, Janout V, Curado MP, Menezes AM, Koifman S, Islami F, Nasrollahzadeh

D, Hu N, Goldstein AM, Gao Y, Ding T, Kamangar F. InterSCOPE – International Collaboration on HPV and Oesophageal Cancer. Presentation at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Smith D. Sexual function five years after a diagnosis of localised prostate cancer: results from the NSW Prostate Cancer Care and Outcomes Study. Presentation at: Urological Society of Australia and New Zealand (USANZ) Supplementary Meeting; 2011 May; Sydney, Australia.

Smith D, Egger S, O’Connell DL, King MT, Berry MP, Stricker PD, Cozzi P, Armstrong BK. Patient-reported quality of life in men diagnosed with advanced prostate cancer: five-year results of the NSW Prostate Cancer Care and Outcomes Study. Presentation at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia. [Nominated for Best of the Best Oral Presentation – Urology].

Smith D, Weber M, Latz I, Korda R, Tikellis G, Patel M, Clements M, Dwyer T, Banks E. Lower urinary tract symptoms in older Australian men: 45 and Up Study. Presentation at: Annual 45 and Up Study Collaborators Meeting; 2011 Sep; Sydney, Australia;

Supramaniam R, O’Connell D. Lower breast cancer survival for Aboriginal women in NSW was not explained by demographic, disease or surgery factors. Presentation at: 3rd Coalition for Research to Improve Aboriginal Health (CRIAH) Aboriginal Health Research Conference; 2011 May 5-6; Sydney, Australia.

Velentzis LS. Dietary patterns and breast cancer recurrence. Presentation at: Annual General Meeting of the Australasian Epidemiological Association; 2011 Nov; Perth, Australia.

Wang S, Li J, Zhao F, Shi JF, Zhang X, Pan Q, Belinson J, Qiao Y. Six-year prospective study on cervical outcomes associated with HPV load. Presentation at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Weber M. Age-related patterns of erectile dysfunction among older men across NSW. Presentation at: Annual General Meeting of the Australasian Epidemiological Association; 2011 Nov; Perth, Australia.

Weber M. Social isolation among older Australian smokers: results from a large population-based cohort. Presentation at: Annual General Meeting of the Australasian Epidemiological Association; 2011 Nov; Perth, Australia.

Weber M, Smith D, O’Connell D, Patel M, DeSouza P, Clements M, Sitas F, Banks E. Age-related patterns of erectile dysfunction among older men across NSW: 45 and Up Study. Presentation at: Annual 45 and Up Study Collaborators Meeting; 2011 Sep; Sydney, Australia.


Willcox S, Stewart B, Sitas F. What do cancer patients think causes their cancer? Presentation at: GP11 – The Conference for General Practice; 2011 Oct 6-8; Hobart, Australia.

Yu XQ, Luo Q, Smith DP, Clements MS, O’Connell DL. Challenges in projecting prevalence for prostate cancer: issues and options. Presentation at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia. [Nominated for Best of the Best Oral Presentation – Epidemiology]

Posters

Armstrong BK, Canfell K, Aminisani N. Participation in recommended cervical screening by Asian and Middle Eastern migrants in Australia: a record linkage study. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Canfell K, Shi JF, Lew JB, Walker R, Smith M, Nickson C, Qiao Y. Predicted long-term outcomes after single-round HPV screening in rural China. Poster presented at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Christian K, Hodgkinson K, Sitas F. Cancer Council NSW biobank: a rich resource for researchers. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Goldsbury D, O’Connell D. Pancreatic cancer surgery and survival in NSW: a population-based observational study using linked data and propensity scoring. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Hodgkinson V, Christian K, Sitas F. Cancer Council NSW biobank: improving blood collection protocols. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Luo Q, Yu XQ, Smith DP, O’Connell DL. Characteristics of men with unknown spread of prostate cancer at diagnosis: analysis of NSW Central Cancer Registry. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Nair-Shalliker V, Smith DP, Egger S, Hughes AM, Kricker A, Armstrong BK. Sun exposure may increase risk of prostate cancer in the high-UV environment of New South Wales, Australia: a case-control study. Poster presented at: 12th Australasian Cancer Conference; 2011 Aug; Melbourne, Australia.

O’Connell D, Carmichael L, Smith D, Gattellari M, Chambers S, Pinnock C, Slevin T, Ward J. Prostate-specific antigen testing awareness

and participation in New South Wales, Australia: demographic, lifestyle and health-related factors. Poster presented at: XIX IEA World Congress of Epidemiology; 2011 Aug 7-11; Edinburgh, Scotland.

O’Connell D, Kahn C, Simonella L, Sywak M, Boyages S, Ung O. Pathways to diagnosis do not explain all of the increase in thyroid cancer: results of a population-based cross-sectional study. Poster presented at: XIX IEA World Congress of Epidemiology; 2011 Aug 7-11; Edinburgh, Scotland.

O’Connell D, Kahn C, Simonella L, Sywak M, Boyages S, Ung O. Post-surgical pathology reporting of thyroid cancer in NSW. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Shi JF, Canfell K, Lew JB, Ma L, Walker R, Zhao F, Smith M, Chen J, Qiao Y. Cost-effectiveness of primary HPV screening in urban populations in China. Poster presented at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Sitas F. InterSCOPE – International Collaboration on HPV and Oesophageal Cancer: pooled seroepidemiological analysis of HPV and oesophageal carcinoma. Poster presented at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Smith D. Sexual function five years after diagnosis of localised prostate cancer: results from the New South Wales (NSW) Prostate Cancer Care and Outcome Study. Poster presented at: Urological Society of Australia and New Zealand (USANZ) 64th Annual Scientific Meeting; 2011 Feb 21-24; Christchurch, New Zealand.

Supramaniam R, Gibberd, A, O’Connell D. Lung cancer treatment and survival for Aboriginal people in NSW: the Aboriginal Patterns of Cancer Care project (APOCC). Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Supramaniam R, O’Connell D. Differences in socioeconomic status, spread of disease, rural residence and access to surgery do not explain lower survival from breast cancer for Aboriginal women. Poster presented at: XIX IEA World Congress of Epidemiology; 2011 Aug 7-11; Edinburgh, Scotland.

Supramaniam R, Rowstorne P, Rodger J, Dillon A, Butow P, Saunders V, O’Connell DL. Developing a questionnaire to explore the pathways to diagnosis of cancer for Aboriginal people in NSW: the Aboriginal Patterns of Cancer Care project (APOCC). Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

36


Supramaniam R, Tang A, O’Connell D. Epidemiology and Indigenous health policy: rising to the challenge. Poster presented at: XIX IEA World Congress of Epidemiology; 2011 Aug 7-11; Edinburgh, Scotland.

Wang S, Li J, Zhao F, Shi JF, Zhang X, Pan Q, Belinson J, Qiao Y. Six-year prospective study on cervical outcomes associated with HPV load. Poster presented at: 27th International Papillomavirus Conference; 2011 Sep 16-22; Berlin, Germany.

Yu XQ, Clements M, O’Connell D. Estimating fraction cured from cancer: which statistical package to use? Poster presented at: XIX IEA World Congress of Epidemiology; 2011 Aug 7-11; Edinburgh, Scotland.

Yu XQ, Clements M, O’Connell D. Projecting prevalence by stage of care for colon cancer and estimating future health service needs in New South Wales, Australia. Poster presented at: XIX IEA World Congress of Epidemiology; 2011 Aug 7-11; Edinburgh, Scotland.

Cancer Information and Support Services Publications

O’Callaghan V. Patients’ perceptions of complementary and alternative medicine. Cancer Forum. 2011;35(1):44-7.

O’Callaghan V. The consumer experience – case studies of complementary therapy use among people diagnosed with cancer. In: Olver I, Robotin M, editors. Perspectives on complementary and alternative medicines. London: Imperial College Press; 2011. p. 373-98.

Presentations

Fitz-Gerald L. Understanding your rights: managing legal and financial issues throughout your cancer journey. Paper presented at: Cancer Nurses Society 14th Winter Congress; 2011 July 21-23; Sydney, Australia.

O’Callaghan V. Aboriginal Cancer Journeys – editing for an Aboriginal audience. Paper presented at: 5th National Editors Conference; 2011 Sep 7-9; Sydney, Australia.

Posters

King S. Engaging in national partnerships to promote the mutual aid model of support through a telephone support group format. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Newling G, Forsyth L. Helping patients with travel and accommodation for treatment. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting;

2011 Nov 15-17; Perth, Australia.

Newling G, Forsyth L. Out-of-area patients in central Sydney. Poster presented at: Clinical Oncological Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

O’Callaghan V, Nance J. Extending the reach: bringing audiovisual cancer resources to deaf and hearing-impaired people. Poster presented at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Wuellner L, Nance J, Batt G, Humphries, E. Cancer, work and you: providing a printed resource for working patients and carers. Poster presented at: Clinical Oncology Society of Australia (COSA) 38th Annual Scientific Meeting; 2011 Nov 15-17; Perth, Australia.

Health Strategies Division Publications

Bonevski B, Girgis A, Magin P, Horton G, Brozek I, Armstrong B. Prescribing sunshine: a cross-sectional survey of 500 Australian general practitioners’ practices and attitudes about vitamin D. Int J Cancer. 2012 May 1;130(9):2138-45. DOI: 10.1002/ijc.26225. Epub 2011 Aug 9.

Bryant J, Bonevski B, Paul C, Hull P, O’Brien J. Implementing a smoking cessation program in social and community service organisations: a feasibility and acceptability trial. Drug and Alcohol Rev. 2011. DOI: 10.1111/j.1465-3362.2011.00391.x. Epub 2011 Dec 6.

Bryant J, Bonevski B, Paul C, O’Brien J, Oakes W. Developing cessation interventions for the social and community service setting: a qualitative study of barriers to quitting among disadvantaged Australian smokers. BMC Public Health. 2011;11:493-500.

Chapman K, Stacey F, Groves E, Pratt IS. After the storm: nutrition after cancer treatment. Cancer Forum. 2011;35(2):77-81.

Dixon H, Scully M, Wakefield M, Kelly B, Chapman K, Donovan R. Parents’ responses to nutrient claims and sports celebrity endorsements on energy-dense and nutrient-poor foods: an experimental study. Public Health Nutr. 2011;14(6):1-9.

Glasson C, Chapman K, James E. Fruit and vegetables should be targeted separately in health promotion programs: differences in consumption levels, barriers, knowledge and stages of readiness for change. Public Health Nutr. 2011;14(4):694-701.

Hebden L, King L, Grunseit A, Kelly B, Chapman K. Advertising of fast food to children on Australian television: the impact of industry self-regulation. Med J Aust. 2011;195(1):20-4.


Hebden L, King L, Kelly B, Chapman K, Innes-Hughes C. A menagerie of promotional characters: promoting food to children through food packaging. J Nutr Educ Behav. 2011;43(5):349-55.

Kelly B, Baur LA, Bauman AE, King L, Chapman K, Smith BJ. Food and drink sponsorship of children’s sport in Australia: who pays? Health Promot Int. 2011;26:188-95.

Kelly B, Baur LA, Bauman AE, King L, Chapman K, Smith BJ. ‘Food company sponsors are kind, generous and cool’: (mis)conceptions of junior sports players. Int J Behav Nutr Phys Act. 2011;8:95.

Kelly B, Baur, LA, Bauman AE, Salah S, Smith BJ, King L, Chapman K. Role modelling unhealthy behaviours: an analysis of food and drink sponsorship of peak sporting organisations. Health Promot J Aust. 2011;22(1):72-5.

Kelly B, Chapman K, King L, Hebden L. Trends in food advertising to children on free-to-air television in Australia. Aust N Z J Public Health. 2011;35:131-4.

James EL, Stacey F, Chapman K, Lubans DR, Asprey G, Sundquist K, Boyes A, Girgis A. Exercise and Nutrition Routine Improving Cancer Health (ENRICH): the protocol for a randomised efficacy trial of a nutrition and physical activity program for adult cancer survivors and carers. BMC Public Health. 2011;11:236-44.

O’Brien J, Geike A, Jardine A, Oakes W, Salmon AM. Integrating smoking care in community service organisations to reach disadvantaged people: findings from the Smoking Matters project. Health Promot J Aust. 2011;21:176-82.

Potente S, Anderson C, Karim M. Environmental sun protection and supportive policies and practices: an audit of outdoor recreational settings in NSW coastal towns. Health Promot J Aust. 2011;22(2):97-101.

Potente S, McIver J, Anderson C, Coppa K. ‘It’s a beautiful day . . . for cancer’: an innovative communication strategy to engage youth in skin cancer prevention. Soc Mar Q. 2011;17(3):86-105.

Scully M, Wakefield M, Niven P, Chapman K, Crawford D, Pratt IS, Baur LA, Flood V, Morley B, NaSSDA Study Team. Association between food marketing exposure and adolescents’ food choices and eating behaviours. Appetite. 2012;58(1):1-5. Epub 2011 Oct 5.

Wellard L, Glasson C, Chapman K. Fries or a fruit bag? Investigating the nutritional composition of fast food children’s meals. Appetite. 2012;58(1):105-10. Epub 2011 Oct 6.

Wellard L, Glasson C, Chapman K, Miller C. Fast facts: the availability and accessibility of nutrition information in fast food chains. Health Promot J Aust. 2011;22(3):184-8.

Winstanley M, Pratt I, Chapman K, Griffin H, Croager E, Olver I, Sinclair C, Slevin T. Alcohol and cancer: a position statement from Cancer Council Australia. Med J Aust. 2011;194:479-82.

Presentations

Buffet K, Rock V, Anderson C. Supporting and empowering childcare centres in disadvantaged communities to become SunSmart. Paper presented at: Australian Health Promotion Association 20th National Conference; 2011 Apr 10-13; Cairns, Australia.

Chapman K. Advocacy on food marketing to children. Paper presented at: Preventing Obesity: moving policy recommendations to action; 2011 Mar 22-23; Ottawa, Canada.

Chapman K. Challenges and opportunities in public health nutrition. Paper presented at: Working Together for a Healthy WA: a settings approach to physical activity, healthy weight and healthy eating; 2011 May 26-27; Perth, Australia.

Gander K. An RCT to evaluate the efficacy of a peer-led nutrition education intervention designed to increase fruit and vegetable consumption. Paper presented at: Annual Meeting of the International Society for Behavioural Nutrition and Physical Activity; 2011 Jun 15-18; Melbourne, Australia.

Hughes C. Evaluating the potential usefulness of fast food menu labelling. Paper presented at: Public Health Association of Australia Food Futures Conference; 2011 Nov 22-23; Hobart, Australia.

Hull P, O’Brien J, Rayson D, Salmon A. Engaging the social and community service sector to help highly disadvantaged smokers. Paper presented at: Oceania Tobacco Control Conference 2011; 2011 Oct 18-20; Brisbane, Australia.

Malpas G, Tang A. Cancer and Local Government: a potent combination. Paper presented at: Making Cities Liveable Conference; 2011 July 28-29; Noosa, Australia.

O’Brien J, Bonevski B, Frost S, Salmon A, Yiow L, Yip S. A survey of the NSW social and community services sector: smoking-related attitudes, policies and practices. Paper presented at: Oceania Tobacco Control Conference 2011; 2011 Oct 18-20; Brisbane, Australia.

O’Brien J, Williams K, Moore R, Jones B. Building capacity in community services to tackle smoking among disadvantaged groups: findings from the Smoking Care project. Paper presented at: Oceania Tobacco Control Conference 2011; 2011 Oct 18-20; Brisbane, Australia.

Penman A. Examining data about tobacco retailers in NSW: what does it tell us? Paper presented at: Oceania Tobacco Control Conference 2011; 2011 Oct 18-20; Brisbane, Australia.

38


Rock V, McIver J. Introducing Sun Sound: a creative approach to mass media. Paper presented at: International Skin Cancer Conference; 2011 May 3-5; Copenhagen, Denmark.

Rock V, McIver J. OMG LOL: using digital media to reposition sun protection for teenagers. Paper presented at: International Skin Cancer Conference; 2011 May 3-5; Copenhagen, Denmark.

Tang A. Intervening in the retail supply of tobacco: the role of licensing retailers. Paper presented at: Oceania Tobacco Control Conference 2011; 2011 Oct 18-20; Brisbane, Australia.

Tang A, Hull P, O’Brien J, Hohnen L, Peters A. Working effectively with the community and social service sector to promote tobacco control activities. Paper presented at: Oceania Tobacco Control Conference 2011; 2011 Oct 18-20; Brisbane, Australia.

Watson W. Advocacy: a role in healthier futures. Paper presented at: Federation of P&C Associations of NSW Annual Conference; 2011 Jul 29-31; Tamworth, Australia.

Watson W. Junkbusters: helping parents navigate self-regulation on food marketing to children. Paper presented at: Annual Meeting of the International Society for Behavioural Nutrition and Physical Activity; 2011 Jun 15-18; Melbourne, Australia.

Watson W. Self-regulation of food marketing to children: is the community concerned? Paper presented at: Public Health Association of Australia Food Futures Conference; 2011 Nov 22-23; Hobart, Australia.

Watson W. ‘We’re all so busy and need energy’: do shoppers understand the term ‘energy’? Paper presented at: Australian New Zealand Obesity Society Conference; 2011 Oct 20-22; Adelaide, Australia.

Wellard L. Fast facts: availability and accessibility of nutrition information in fast food outlets. Paper presented at: Public Health Association of Australia Conference; 2011 Sep 26-28; Brisbane, Australia.

Wellard L. Observation of healthy and unhealthy purchases at fast food stores. Paper presented at: Public Health Association of Australia Conference; 2011 Sep 26-28; Brisbane, Australia.

Williams K. Building capacity in community services to tackle smoking among disadvantaged groups: the Smoking Care project. Paper presented at: Australian Health Promotion Association 20th National Conference; 2011 Apr 10-13; Cairns, Australia.

Williams K, Butler J. A critical piece of the puzzle: consumer action and advocacy for tobacco control. Paper presented at: Oceania Tobacco Control Conference 2011; 2011 Oct 18-20; Brisbane, Australia.

Posters

Chapman K, Watson W, Kelly B, King L, Glasson C, Wellard L, Gill T. Understanding nutrition literacy in relation to front-of-pack food labelling. Poster presented at: Annual Meeting of the International Society for Behavioural Nutrition and Physical Activity; 2011 Jun 15-18; Melbourne, Australia.

Chapman K, Watson W, Kelly B, King L, Glasson C, Wellard L, Gill T. Understanding nutrition literacy in relation to front-of-pack food labelling. Poster presented at: Public Health Association of Australia Conference; 2011 Sep 26-28; Brisbane, Australia.

Hull P, O’Brien J, Salmon A, Rayson D. Much needed, long overdue: working with community service organisations to tackle tobacco amongst disadvantaged smokers. Poster presented at: Australian Health Promotion Association 20th National Conference; 2011 Apr 10-13; Cairns, Australia.

Watson W, Chapman K, Mackay S, Martin J. Food marketing complaints registry: helping parents navigate self-regulation. Poster presented at: Public Health Association of Australia Conference; 2011 Sep 26-28; Brisbane, Australia.

Wellard L, Glasson C, Chapman K, Miller C. Fast facts: availability and accessibility of nutrition information in fast food outlets. Poster presented at: Annual Meeting of the International Society for Behavioural Nutrition and Physical Activity; 2011 Jun 15-18; Melbourne, Australia.

Wellard L, Glasson C, Chapman K, Miller C. Fast facts: availability and accessibility of nutrition information in fast food outlets. Poster presented at: Public Health Association of Australia Conference; 2011 Sep 26-28; Brisbane, Australia.


Cancer Council NSW Board of Directors

Mr Bruce Hodgkinson SC (Chair)Barrister, Denman Chambers

Dr Stephen AcklandStaff Specialist, Medical Oncology, Calvary Mater Newcastle Hospital

Ms Jill Boehm OAM (Deputy Chair)

Ms Mary ChiewManaging Director, Giorgio Armani Australia

Dr Patrick CreganAssociate Professor of Surgery, University of Western Sydney

Mr Paul LahiffConsultant

Prof Graham MannProfessor in Medicine, University of Sydney at Westmead Institute for Cancer Research

Mr Stephen Roberts Senior Partner, Asia Pacific for Mercer Investments

Mr Bob SendtConsultant and former NSW Auditor-General

Ms Melanie TrethowanConsultant

Cancer Council NSW Cancer Research Committee

Prof Michelle Haber AM (Chair)Professor, Executive Director and Head of Experimental Therapeutics Program, Children’s Cancer Institute Australia for Medical Research

Prof Mark Baker Professor of Proteomics, Macquarie University

Ms Jane BennettConsumer Representative

Prof Andrew BiankinProfessor and Head, Pancreatic Cancer Research, Garvan Institute of Medical Research

A/Prof Anna deFazioHead, Gynaecological Oncology Research Group, Westmead Institute for Cancer Research

Prof Sandra JonesProfessor and Director, Centre for Health Initiatives, University of Wollongong

Prof Reg Lord AMProfessor and Head, Gastroesophageal Cancer Research Program, and Upper Gastrointestinal Surgeon, St Vincent’s Hospital

Mr John MoroneyConsumer Representative

Dr Andrew Penman AMCEO, Cancer Council NSW

Dr Melanie PriceSenior Research Fellow, Centre for Medical Psychology and Evidence-based Decision-making (CeMPED), and Executive Director, Psycho-Oncology Co-operative Research Group (PoCoG), University of Sydney

Dr Monica RobotinMedical Director, Cancer Council NSW, and Senior Lecturer in Public Health, University of Sydney

A/Prof Natalka SuchowerskaHead, Research and Education (Medical Physics), Department of Radiation Oncology, University of Sydney

Prof Kate WhiteProfessor of Nursing and the Cancer Institute of NSW Chair in Cancer Nursing, University of Sydney

Cancer Council NSW Ethics Committee

Ms Meghan Carruthers (Chair)Senior Associate, HWL Ebsworth

Ms Amanda AdrianLaywoman

Mr Bill McCarthy AMMedical Graduate with Research Experience

Dr Graeme MorganMedical Graduate with Research Experience

Ms Joanne MullerLawyer

Rev John NeaseyReligious Representative

Mr Felix RatcliffAllied Health Professional

Dr Monica RobotinMedical Graduate with Research Experience

Dr John Sanders (Deputy Chair) Layman

Research Review Committee

Prof Louisa Jorm (Chair)Research Director, Sax Institute

Ms Gillian BattDirector, Cancer Information and Support Services Division, Cancer Council NSW

Mr Jim GraindaConsumer Representative

Dr Monica RobotinMedical Director, Cancer Council NSW

A/Prof Freddy SitasDirector, Cancer Research Division, Cancer Council NSW

Board and committees

40

Board and committees

Designed by Cobe DesignPrinted by SOS Print + MediaPhotography by Christian Trinder

© Cancer Council NSW 2012 ABN 51 116 463 846

CAN2038 06/12

ContactCancer Research Division

Cancer Council NSW PO Box 572 Kings Cross NSW 1340

P: 02 9334 1837 F: 02 8302 3550 E: [email protected]

Research Strategy Unit

Cancer Council NSW PO Box 572 Kings Cross NSW 1340

P: 02 9334 1854 E: [email protected]

153 Dowling Street Woolloomooloo NSW 2011

Donations Hotline 1300 780 113 [email protected] www.cancercouncil.com.au

Documents

The untold story - Cancer Council NSW - Cancer Prevention ... · Cancer Council NSW connects people and organisations to the cancer cause. Together we can build insights into the